Feeds:
Posts
Comments

Posts Tagged ‘Synthetic biology’

From Genomics of Microorganisms to Translational Medicine

Reporter and Curator: Demet Sag, PhD

Pharmacogenomics needs new materials that are inert against the host and specifically  active to modulate molecular metabolism towards wanted homeostasis of the physiological system.  These can come from natural resources or men-made.  That is why we must know the origin  to  improve.     Recently, Synthetic Biology, even though it is a developing upcoming field, it is generating mile stones for applications in the clinic, the biotechnology industry and in basic molecular research. As  a result, it created a multidisciplinary expertise from scientists to engineers.  Among other things extending the search to first life on Earth is one of the many alternatives.  Here I like to present how synthetic biology can be initiated onto Translational Medicine from adiscovery of molecules from the sea.

Microorganisms played a role in evolution to start a life.  99 % of our genome is related to microbial organisms. initially there was a classical  Microbiology, then evolved to Industrial Microbiology and Biotechnology then Microbial Genomics and now Microbiome and Health became the focus.  Finally,  the circle is getting tide into how microbiome involved with healthy and disease state of human? How they can be used that is what it really means to include microorganisms into human health for diagnostics and targeted therapies?

Or should we start from  scarcity?

Microbiology is my first formal education and  building block.  Simple but help to understand system biology and  the mechanism of life in a nut shell.   The closest field is embryonic stem cell biology for building “synthesizing” a whole new organism.  Then  system biology and developmental biology also gain interest.

The real  remember the month of October in 2001 when DOE reported that they sequenced 23 organisms in Walnut Creek.  Having seen presentation to identify microorganisms through complex crystal structure assays through chemical pathway  at the Microbial Genomics Meeting organized by ASM in Monterey, CA in 2001.

Discovery of microorganisms in marine life like in Mediterranean Sea, containing 38% salt,is very similar with finding circulating disease making cells.   Yet, they are similar since both search for a specific needle in the pile.  Furthermore, the unique behavior of enzymes from microbial organisms such as Taq polymerase or restriction enzymes made it possible for us to develop new technologies for copying and propagating significant sequences.  When these early molecular biology methods are combined with the power of genomics and knowledge of unique structures in molecular physiology, it is possible to design better and sensitive sensors or build an organism to rptect or fix the need of the body.  neither sensors nor synthesized organism model are complete since one is missing the basic element of life “transformation of information” the other is missing the integrity that once nature provided in a single simple cell.

Having sensory smart chip/band/nanomolecule to redesign the cells may also possible if only we know the combination.  Thus, we have options to deliver if we know what to be carried.

An external file that holds a picture, illustration, etc.<br /><br /><br /><br /><br /> Object name is marinedrugs-11-00700-g002.jpg

(Figure: The combined strategy of gene-based screening and bioactivity-based screening for marine microbial natural products (MMNPs) discovery, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705366/figure/marinedrugs-11-00700-f002/)

As we come across, novel pathways or primary pathways of physiology gain significant interest to determine marine microbial compound for therapeutics since they are further away from the evolution three that gives an advantage for biomedical/translational scientist to avoid most part of th eimmune responses such as inflammation, toxicity. Yes, indeed these are not scientific tails but true since currently, 16 of 20 marine antitumor compounds under clinical trial are derived from microbial sources because marine microorganisms are a major source for MMNP discovery.  However, isolation of these organisms.  For example, pretreatment methods, enrichment, physical, and chemical techniques (e.g., dry heat, exposure to 1%–1.5% phenol, sucrose-gradient centrifugation, and filtration through cellulose membrane filters) can be applied to increase especially the less abundant specific groups of marine microorganisms, . A variety of pretreatment methods including recovery of these microorganisms.  This reminds me ecosystem of the soil, since in soil the trouble is identifying the specific culture among millions of others.

Regardless of the case,  nutrients are the key for selecting and isolating any organisms but specifically, as a result any marine microbes have specific nutrient requirements for growth (e.g., sponge extract ) or chemical (e.g., siderophores, signal molecules, non-traditional electron donors, and electron acceptors.  This also should remind us subject of Biology 101 Essential Vitamins and Minerals.  What we eat who we are.

For example, Bruns et al. employed technique where they employed different carbon substrates (agarose, starch, laminarin, xylan, chitin, and glucose) at low concentrations (200 μM each) so that they can  improve the cultivation efficiency of bacteria from the Gotland Deep in the central Baltic Sea. As a result of this growth medium they were able to elevate yield, which is created higher cultivation efficiencies (up to 11% in fluid media) compared to other studies.

Yet, another component must be addressed that is culture medium such as ionic strength for a microbila growth. For example, Tsueng et al. study on marine actinomycete genus Salinispora that can produce bioactive secondary metabolites such as desferrioxamine, saliniketals, arenamides, arenimycin and salinosporamide.  However, they observed that  three species of SalinisporaS. arenicolaS. tropica, and S. pacifica require a high ionic strength but  S. arenicolahas a lower growth requirement for ionic strength than S. tropica and S. pacificaUsing after assaying them against sodium chloride-based and lithium chloride-based media. As  aresult, there is a specificity for growth. 

In addition, energy must be supported imagine that in marine organisms the metabolism is very unique, may be slow and possibly.  However, the main criteria is  most of them grow under low oxygen conditions like tumors.  Warburg effect posed a  problem for human but helped microorganisms to survive and evolve.  One’s weakness the other’s strength make a great teamwork for solving diseases of human kind es especially for cancer. 

This reminds us to utilize minerals, electrons specifically after all the simplest form of carbon metabolism based on biochemical pathways like Crebs cycle, one carbon metabolism and amino acid metabolism etc. Even though 90% of human body made up off microbial origin there are microorganisms that are not cultured yet.

The irony is less than 1% of microorganisms can be cultured.  Furthermore, they are not included for representing the total phylogenetic diversity. Therefore, majority of work concentrated on finding and cultivating the uncultured majority of the microbial world for MMNPs’.  For example,  an uncultivated bacterial symbiont of the marine sponge Theonella swinhoei  producing many antitumor compounds such as pederin, mycalamide A, and onnamide A.

In any conditions if any living needs to be recognized and remembered, their place would be either on top or the bottom of the stack. Microbiome searches for specificity among tone of other organisms to recognize the disease, changes in cell differentiation and pathways or marine microbiologist search for uncommon scarce organisms. Yet, both of them are beneficial with their unique way.

Then what is the catch or fuss?  The catch is screening to identify what makes this organism unique that can be use for human health. Translational medicine may start from the beginning of life from microorganisms created.  This can be called with its newly coined named”synthetic biology” but if we go further than the conventional screening methods which include bioactivity-guided screening and gene-guided screening  and increase the power with genomics we may call it “synthetic genomics”.

As  a result these signature sequences establishes the “unique” biomarkers  or therpaeutics to be used for drug discovery, making vaccines, and remodulating the targeted cells. How?

These microorganisms secrete these metabolites or proteins to their growth medium just like a soluble protein, if you will like a inflammation factor or any other secreted protein of our human body cells. Collecting substrate or extract the pellet could be the choice.   in a nut shell this require at least three steps: First, finding the bioactivity, apply bioactivity-guided screening for direct detection of  the activity such as antimicrobial, antitumor, antiviral, and antiparasitic activities.  Second, a bioinformatic assessment of the secondary metabolite biosynthetic potential in the absence of fully assembled pathways or genome sequences. Third, application on cell lines and possible onto model organisms can improve the process of MMNP discovery so that allow us to prioritize strains for fermentation studies and chemical analysis. 

In summary, establish the culture growth, analyze bioactivity and discover the new gene product to be used.  Here is an example, first they  isolated Marinispora sp from the saline culture.  Next step,  identify new sources of bioactive secondary metabolites, gene-guided screening has been deployed to search target genes associated with NPs biosynthetic pathways, e.g., the fragments between ketosynthase and methylmalonyl-CoA transferase of polyketides (PKS) type I, enediyne PKS ketosynthase gene, O-methyltransferase gene, P450 monooxygenase gene, polyether epoxidase gene, 3-hydroxyl-3-methylglutaryl coenzyme A reductase gene, dTDP-glucose-4,6-dehydratase (dTGD) gene, and halogenase gene. The, apply bioinformatics that includes synthesizing the knowledge with  homology-based searches and phylogenetic analyses, gene-based screening  to predict new secondary metabolites discovered by isolates or environments.  Finally, identify the sequnce for PCR and use against a cell line or model organisms. In this case,  CNQ-140 based on significant antibacterial activities  against drug-resistant pathogens (e.g., MRSA) and impressive and selective cancer cell cytotoxicities (0.2–2.7 μM of MIC50 values) against six melanoma cell lines provided significant outcome. They are recognized as antitumor antibiotics with a new structural class, marinomycins A–D

This is a great method but there are two botle necks: 1. 99% of microbial organisms are not cultured in the labs. 2. Finding the optimum microbial growth and screening takes time. Thus, assesments can me done through metagenomics.  However, metagenomics has its shortcomings since on face of living unless applications applied in vivo in vitro results may not be valid.  The disadvantage of  metagenomics can be listed as:  1. inability of efficient acquisition of intact gene fragment,  2. incompatibility of expression elements such as promoter in a heterologous host.  On the pther hand, there can be possible resolution to avoid these factors  so metagenomics-based MMNP discovery can be plausable such as development  in  synthetic biology by large DNA fragment assembly techniques for artificial genome synthesis and synthetic microbial chassis suitable for different classes of MMNP biosynthesis.

However, many gene clusters have been identified by combined power of genomics and biioinformatics for MNP discovery.  This is  mainly necessary since  secondary metabolites usually biosynthesized by large multifunctional synthases that acts in a sequential assembly lines like adding carboxylic acid and amino acid building blocks into their products.  

 References

Simmons TL, Coates RC, Clark BR, Engene N, Gonzalez D, Esquenazi E, Dorrestein PC, Gerwick W

Proc Natl Acad Sci U S A. 2008 Mar 25; 105(12):4587-94.

Read Full Post »

Food Insecurity in Africa and GMOs

Reporter and Curator: Larry H. Bernstein, MD, FCAP 

Article ID #103: Food Insecurity in Africa and GMOs. Published on 1/13/2014

WordCloud Image Produced by Adam Tubman

 

This Report is a presentation from several articles since mid-2013 on the food shortage in Sub-Saharan Africa, where crop yields are among the lowest in the worlds.  In this series we have presented modiable  and epigenetic causes of CVD, among other topics, including diabetes, obesity, and exercise.  We have mentioned that while magnesium, fiber, a sufficient source of n-3 polyunsaturated fatty acids (from seafood or seaweed, or from flaxseed), and a functional methyl transporter as well as a source of methionine ( which requires a meat source, as B9 folate is plant sourced and does not fix the problem).  In this discussion we have both a voluntary and an involuntary course of living that leads to CVD and brain dysfunction, depending on where one lives, a “perfect storm”.

Part 1.  Tensions over Food Insecurity in Africa   Oct 8, 2013

Sharon Schmickle

Sub-Saharan Africa’s agricultural yields are among the lowest in the world, and nearly one-third of its people are malnourished. That much, tragically, is well established. Less clear are the reasons Africa’s farm output remains depressed despite hands-on work and billions of dollars invested by individuals, organizations and governments. News reports often explore specific aspects of the problem such as drought. This series takes the novel approach of looking at intertwined tensions underlying the many problems. Through stories told across the continent, Sharon Schmickle focus on several key themes:

  • Africa is caught in an ideological struggle over the nature and scope of agriculture with European—and, sometimes, American—organizations pitted against agribusiness and many agricultural scientists.
  • Institutions have failed African farmers. Public and private agencies often work at cross purposes, neglecting to follow through on crop-saving opportunities. Investments in research and agricultural extension have been inadequate.

Scientists have made impressive gains against the scourges that threaten crops. But they risk losing their breakthroughs against malnutrition, crop-destroying pests and drought if they overlook local tastes and customs.

The series, which also incorporates the work of local journalists, begins with an overview of Tanzania where government officials are divided in the global ideological standoff. Despite a government initiative called Kilimo Kwanza (Farmers First), many farmers lack access to the improved seeds and tissue cultures that could help them thwart yield-stealing diseases and pests. And many farmers are so locked into practices of the past that change comes hard if at all.

This narrative is not twisted to an anti-GMO slant, and could be viewed as a need for GMO harvests without the independence to develop them, and the struggle against a powerful industrial source that takes from an impoverished people.

Sharon Schmickle has been a journalist for MinnPost.com since 2007, and before that she worked for the Minneapolis Star Tribune where she reported from the paper’s Washington bureau…

http://pulitzercenter.org/sites/default/files/styles/responsive_cropped/public/09-16-13/1382/lunch_line_at_engaruka_primary_school_0.jpg

Roiling tensions underlie efforts to improve food security in Africa, often pulling at cross purposes on farmers, consumers and their countries.

Tanzania: Mixed Feelings on Genetically Modified Crops
Tanzania faces the question of whether food from GM crops will sell at markets like this one in Dar es Salaam. Image by Sharon Schmickle. Tanzania, 2013.

Part 2.  Nathanael Johnson lets the anti-GMO movement off the hook

By MICHAEL EISEN | Published: JAN 10, 2014

For the last six months, Nathanael Johnson has been writing about GMOs for the lefty environmental magazine Grist. The goal of his ultimately 26 part series was to try and bring some journalistic sanity to a topic that has gotten nasty in recent years. As Grist editor Scott Rosenberg is quoted on Dan Charles’ blog:
GMOs “were a unique problem for us,” says Rosenberg. On the one hand, most of Grist’s readers and supporters despise GMOs, seeing them as a tool of corporate agribusiness and chemical-dependent farming.

On the other hand, says Rosenberg, he’d been struck by the passion of people who defended this technology, especially scientists. It convinced him that the issue deserved a fresh look.

I’ve enjoyed reading the series. Johnson has investigated a wide range of issues related to GMOs with a generally empirical eye – trying to find data to help answer questions, while avoiding the polemicism that dominates discussions of the topic. Although I don’t think everything he has written is right, the series is a very useful starting point for people trying to wrap the heads around what can be a complex topic. He has clearly tried to delve deeply into every topic, and to not let dogma or propaganda from either side affect his conclusions.

Unfortunately, if the series has had an effect on what I presume is its target audience – the anti-GMO readers of Grist – it hasn’t shown up in online debates about GMOs. When I and others have pointed to Johnson’s series in response to outrageous statements from anti-GMO campaigners, he is dismissed as either a naive fool or just another Monsanto tool.

So I was surprised to read his concluding piece in the series, “What I learned from six months of GMO research: None of it matters“.

The most astonishing thing about the vicious public brawl over GMOs is that the stakes are so low.

His basic point is that a lot of hot air and political energy is spent trying to decide between two alternative futures that aren’t all that different.

In the GMO-free future, farming still looks pretty much the same. Without insect-resistant crops, farmers spray more broad-spectrum insecticides, which do some collateral damage to surrounding food webs. Without herbicide-resistant crops, farmers spray less glyphosate, which slows the spread of glyphosate-resistant weeds and perhaps leads to healthier soil biota. Farmers also till their fields more often, which kills soil biota, and releases a lot more greenhouse gases.

The banning of GMOs hasn’t led to a transformation of agriculture because GM seed was never a linchpin supporting the conventional food system: Farmers could always do fine without it. Eaters no longer worry about the small potential threat of GMO health hazards, but they are subject to new risks: GMOs were neither the first, nor have they been the last, agricultural innovation, and each of these technologies comes with its own potential hazards. Plant scientists will have increased their use of mutagenesis and epigenetic manipulation, perhaps. We no longer have biotech patents, but we still have traditional seed-breeding patents. Life goes on.

In the other alternate future, where the pro-GMO side wins, we see less insecticide, more herbicide, and less tillage. In this world, with regulations lifted, a surge of small business and garage-biotechnologists got to work on creative solutions for the problems of agriculture.

Genetic engineering is just one tool in the tinkerer’s belt. Newer tools are already available, and scientists continue to make breakthroughs with traditional breeding. So in this future, a few more genetically engineered plants and animals get their chance to compete. Some make the world a little better, while others cause unexpected problems. But the science has moved beyond basic genetic engineering, and most of the risks and benefits of progress are coming from other technologies. Life goes on.

In many ways he’s right. GMOs on the market today – and most of the ones planned – are about making agriculture more efficient and profitable for farmers and seed providers. This is not a trivial thing, but would global agriculture collapse without these GMOs? Of course not.

We rarely see transformative technologies coming. And remember that we are still in the very early days of genetic engineering of crops and animals. I suspect that you could go back and look at the early days of almost any new technology and convincingly downplay its transformative potential.

Most new technologies ultimately fail to deliver. But the proper stance to take is to say that we just don’t know. What we do know is that there are many pressing and complex problems facing the future of agriculture. And, given that there is no compelling reason not to allow GM techniques to proceed, why take this tool out of the hands of scientists?

People care about GMOs because they symbolize corporate control of the food system, or unsustainable agriculture, or the basic unhealthiness of our modern diet. On the other side, people care about GMOs because they symbolize the victory of human ingenuity over hunger and suffering, or the triumph of market forces, or the wonder of science.

What is most disturbing about the GMO debate – and why it matters – is that the anti-GMO movement at almost every turn rejects empiricism as a means of understanding the world and making decisions about it. GMO opponents have largely rejected Johnson and his series.

They do not appear to believe that the kind of questions that Johnson asks – “Does insect resistant corn reduce the amount of insecticide used on farms?” – can even be asked. They already know the answer, and are completely unmoved by evidence.

The world faces so many challenges now, and we can only solve them if we believe that the world can be understood by studying it, that we can think up and generate possible solutions to the challenges we face, and that we can make rational decisions about which ones to use or not to use.

– See more at: http://www.michaeleisen.org/blog/?p=1530#sthash.GVFidZev.dpuf

Part 3.  Africa: Context is Crucial to Seeing Challenge of Hunger

October 17, 2013 / Des Moines Register
http://pulitzercenter.org/sites/default/files/styles/slideshow/public/10-16-13/farmerprocessingmilkintobutter640.jpg

Women farmers are processing more of their milk. Image by Sharon Schmickle. Tanzania, 2013.

To understand food security in sub-Saharan Africa, context is crucial. Some 500 million small farms feed 80 percent of the people who live in regions that are perilously close to hunger.
Published Oct 17, 2013  SHARON SCHMICKLE

Iowans who take in this year’s World Food Prize Borlaug Dialogue in Des Moines can gain a wealth of expert perspectives on the important challenge of nourishing a growing world population during the next century.
Learning the full measure of the challenge, though, calls for reaching beyond the lectures and panel discussions — reaching into the local reasons it has been so difficult to achieve global food security.
Context is crucial in a world where some 500 million small farms feed 80 percent of the people who live in regions that are perilously close to hunger.
To visit farms in those regions is to learn why it has been so difficult to stand up to the moral challenge the late Norman Borlaug delivered time and again, insisting that access to adequate food is a basic human right.
It is to meet female farmers like Sharifa Said Nambanga, who struggles to feed five children with the rice she can grow on a small plot in Zanzibar. Women do a hefty share of the farm work around the world. Often, though, they are shut off from the extension services that should deliver improved seeds, fertilizer and the know-how to use agriculture’s modern methods. Feeling abandoned, they limp along as best they can on their own.
It is to meet pastoralists like Parmelo Ndiimu. He is a Maasai elder who watches helplessly while the trees he needs to feed his goats are cut to make charcoal for cooking in urban kitchens. “If we won’t be able to feed our goats, we will not be able to feed our children,” Ndiimu said. “And we will be gone.”
It is to meet Tanzanian farmers who work their small plots throughout a full growing season only to see weevils destroy half their bean harvest. They know firsthand the tension between farmers and the ever evolving pests that attack crops in the field and after harvest.
It is to see corn planted from family seed wither in the field, stalks barren and green leaves giving way to limp yellow strips. Theoretically, the simple remedy should be improved seeds. But nothing is simple in the process of getting those improved seeds to small-scale farmers, especially when the improvement involved genetic modification of the plants.
In his later years, Borlaug addressed context in sub-Saharan Africa, recognizing that along with improved seed, farmers also needed to knock down barriers in their marketing, storage and processing systems. He challenged African leaders to invest more in agriculture.
Within that framework, it is clear that millions of small-scale farmers — especially those in Africa — operate amid tensions that limit their opportunities to extract more food from the technology that has filled porridge bowls and bread baskets elsewhere.

Part 4. Betting on the Impact of Synthetic Biology In Healthcare – By Jenny Rooke

Jenny Rooke drives innovation in the life sciences field through investing and business building around brilliant scientists and engineers with novel technologies. Prior, Jenny held multiple executive roles at U.S. Genomics.

I am an ardent believer in the potential of synthetic biology – its technologies, methods, and talented practitioners – to transform human life on just about every dimension: What we eat, how we make things, the character of our environment and how we move through it, how we are born, and, eventually, how long we live.

My more circumspect investor side is forced to admit that the evidence base of practical (not to mention profitable) applications of synthetic biology remains, shall we say, a work in progress. The first wave of synthetic biology companies that focused on energy/biofuels has been largely disappointing commercially, despite some notable technical successes, due in part to challenges related to scale-up, feedstock economics, and distribution.

It seems reasonable to search for proof cases of synthetic biology’s utility in human health; after all, the vast majority of biotechnology’s impact to date (practically and financially) has been in healthcare, including the creation of entirely novel categories of therapeutics and molecular diagnostics.

To be fair, it’s early yet to expect too many synthetic biology success stories in medicine. Synthetic biology as a field is just over a decade old and if it takes on average a decade for a new drug to move from the lab to the market, well, the math is obvious. In addition, there remain a great deal of technical, clinical, and safety risk inherent to applying synthetic biology technologies to human health problems (consider the painful lessons from the analogous field of gene therapy). This helps explain the reluctance of incumbent healthcare companies and traditional healthcare investors to make big bets on synthetic biology until the technology’s practical utility is more proven.

In 2011 and 2012, the Bill & Melinda Gates Foundation put out a call for grant applications to “Apply Synthetic Biology to Global Health Challenges” under its Global Health division, which aims to harness advances in science and technology to save lives in developing countries. The foundation’s Grand Challenges Explorations, or GCE, program is an ideal mechanism for fostering applications of synthetic biology.

Synthetic biology will play a critical role in enabling novel, affordable healthcare solutions for developing countries. Image source: GrandChallenges.org

For more information on the Grand Challenges in Global Health program, including a brief description of each project and a discussion of observed themes, see the review article “Synthetic biology as a source of global health innovation” (Syst Synth Biol (2013) 7:67–72).

Read Full Post »

Synthetic Biology: On Advanced Genome Interpretation for Gene Variants and Pathways: What is the Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging

Curator: Aviva Lev-Ari, PhD, RN

Article ID #52: Synthetic Biology: On Advanced Genome Interpretation for Gene Variants and Pathways: What is the Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging. Published on 5/17/2013

WordCloud Image Produced by Adam Tubman

UPDATED on 7/12/2021

  • Abstract. Synthetic biology is a field of scientific research that applies engineering principles to living organisms and living systems.
  • Introduction. This article is intended as a perspective on the field of synthetic biology. …
  • Genetic Manipulation—Plasmids. …
  • Genetic Manipulations—Genome. …
  • An Early Example of Synthetic Biology. …

UPDATED on 11/6/2018

Which biological systems should be engineered?

To solve real-world problems using emerging abilities in synthetic biology, research must focus on a few ambitious goals, argues Dan Fletcher, Professor of bioengineering and biophysics, and chair of the Department of Bioengineering at the University of California, Berkeley, USA. He is also a Chan Zuckerberg Biohub Investigator.
Start Quote

Artificial blood cells. Blood transfusions are crucial in treatments for everything from transplant surgery and cardiovascular procedures to car accidents, pregnancy-related complications and childhood malaria (see go.nature.com/2ozbfwt). In the United States alone, 36,000 units of red blood cells and 7,000 units of platelets are needed every day (see go.nature.com/2ycr2wo).

But maintaining an adequate supply of blood from voluntary donors can be challenging, especially in low- and middle-income countries. To complicate matters, blood from donors must be checked extensively to prevent the spread of infectious diseases, and can be kept for only a limited time — 42 days or 5 days for platelets alone. What if blood cells could be assembled from purified or synthesized components on demand?

In principle, cell-like compartments could be made that have the oxygen-carrying capacity of red blood cells or the clotting ability of platelets. The compartments would need to be built with molecules on their surfaces to protect the compartments from the immune system, resembling those on a normal blood cell. Other surface molecules would be needed to detect signals and trigger a response.

In the case of artificial platelets, that signal might be the protein collagen, to which circulating platelets are exposed when a blood vessel ruptures5. Such compartments would also need to be able to release certain molecules, such as factor V or the von Willebrand clotting factor. This could happen by building in a rudimentary form of exocytosis, for example, whereby a membrane-bound sac containing the molecule would be released by fusing with the compartment’s outer membrane.

It is already possible to encapsulate cytoplasmic components from living cells in membrane compartments6,7. Now a major challenge is developing ways to insert desired protein receptors into the lipid membrane8, along with reconstituting receptor signalling.

Red blood cells and platelets are good candidates for the first functionally useful synthetic cellular system because they lack nuclei. Complex functions such as nuclear transport, protein synthesis and protein trafficking wouldn’t have to be replicated. If successful, we might look back with horror on the current practice of bleeding one person to treat another.

Micrograph of red blood cells, 3 T-lymphocytes and activated platelets

Human blood as viewed under a scanning electron microscope.Credit: Dennis Kunkel Microscopy/SPL

Designer immune cells. Immunotherapy is currently offering new hope for people with cancer by shaping how the immune system responds to tumours. Cancer cells often turn off the immune response that would otherwise destroy them. The use of therapeutic antibodies to stop this process has drastically increased survival rates for people with multiple cancers, including those of the skin, blood and lung9. Similarly successful is the technique of adoptive T-cell transfer. In this, a patient’s T cells or those of a donor are engineered to express a receptor that targets a protein (antigen) on the surface of tumour cells, resulting in the T cells killing the cancerous cells (called CAR-T therapies)10. All of this has opened the door to cleverly rewiring the downstream signalling that results in the destruction of tumour cells by white blood cells11.

What if researchers went a step further and tried to create synthetic cells capable of moving towards, binding to and eliminating tumour cells?

In principle, untethered from evolutionary pressures, such cells could be designed to accomplish all sorts of tasks — from killing specific tumour cells and pathogens to removing brain amyloid plaques or cholesterol deposits. If mass production of artificial immune cells were possible, it might even lessen the need to tailor treatments to individuals — cutting costs and increasing accessibility.

To ensure that healthy cells are not targeted for destruction, engineers would also need to design complex signal-processing systems and safeguards. The designer immune cells would need to be capable of detecting and moving towards a chemical signal or tumour. (Reconstituting the complex process of cell motility is itself a major challenge, from the delivery of energy-generating ATP molecules to the assembly of actin and myosin motors that enable movement.)

Researchers have already made cell-like compartments that can change shape12, and have installed signalling circuits within them13. These could eventually be used to control movement and mediate responses to external signals.

Smart delivery vehicles. The relative ease of exposing cells in the lab to drugs, as well as introducing new proteins and engineering genomes, belies how hard it is to deliver molecules to specific locations inside living organisms. One of the biggest challenges in most therapies is getting molecules to the right place in the right cell at the right time.

Harnessing the natural proclivity of viruses to deliver DNA and RNA molecules into cells has been successful14. But virus size limits cargo size, and viruses don’t necessarily infect the cell types researchers and clinicians are aiming at. Antibody-targeted synthetic vesicles have improved the delivery of drugs to some tumours. But getting the drug close to the tumour generally depends on the vesicles leaking from the patient’s circulatory system, so results have been mixed.

Could ‘smart’ delivery vehicles containing therapeutic cargo be designed to sense where they are in the body and move the cargo to where it needs to go, such as across the blood–brain barrier?

This has long been a dream of those in drug delivery. The challenges are similar to those of constructing artificial blood and immune cells: encapsulating defined components in a membrane, incorporating receptors into that membrane, and designing signal-processing systems to control movement and trigger release of the vehicle’s contents.

The development of immune-cell ‘backpacks’ is an exciting step in the right direction. In this, particles containing therapeutic molecules are tethered to immune cells, exploiting the motility and targeting ability of the cells to carry the molecules to particular locations15.

A minimal chassis for expression. In each of the previous examples, the engineered cell-like system could conceivably be built to function over hours or days, without the need for additional protein production and regulation through gene expression. For many other tasks, however, such as the continuous production of insulin in the body, it will be crucial to have the ability to express proteins, upregulate or downregulate certain genes, and carry out functions for longer periods.

Engineering a ‘minimal chassis’ that is capable of sustained gene expression and functional homeostasis would be an invaluable starting point for building synthetic cells that produce proteins, form tissues and remain viable for months to years. This would require detailed understanding and incorporation of metabolic pathways, trafficking systems and nuclear import and export — an admittedly tall order.

It is already possible to synthesize DNA in the lab, whether through chemically reacting bases or using biological enzymes or large-scale assembly in a cell16. But we do not yet know how to ‘boot up’ DNA and turn a synthetic genome into a functional system in the absence of a live cell.

Since the early 2000s, biologists have achieved gene expression in synthetic compartments loaded with cytoplasmic extract17. And genetic circuits of increasing complexity (in which the expression of one protein results in the production or degradation of another) are now the subject of extensive research. Still to be accomplished are: long-lived gene expression, basic protein trafficking and energy production reminiscent of live cells.

End Quote

SOURCE

https://www.nature.com/articles/d41586-018-07291-3?utm_source=briefing-dy&utm_medium=email&utm_campaign=briefing&utm_content=20181106

UPDATED on 10/14/2013

Genetics of Atherosclerotic Plaque in Patients with Chronic Coronary Artery Disease

372/3:15 Genetic influence on LpPLA2 activity at baseline as evaluated in the exome chip-enriched GWAS study among ~13600 patients with chronic coronary artery disease in the STABILITY (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY) trial. L. Warren, L. Li, D. Fraser, J. Aponte, A. Yeo, R. Davies, C. Macphee, L. Hegg, L. Tarka, C. Held, R. Stewart, L. Wallentin, H. White, M. Nelson, D. Waterworth.

Genetic influence on LpPLA2 activity at baseline as evaluated in the exome chip-enrichedGWASstudy among ~13600 patients with chronic coronary artery disease in the STABILITY (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY) trial.

L. Warren1, L. Li1, D. Fraser1, J. Aponte1, A. Yeo2, R. Davies3, C. Macphee3, L. Hegg3,

L. Tarka3, C. Held4, R. Stewart5, L. Wallentin4, H. White5, M. Nelson1, D.

Waterworth3.

1) GlaxoSmithKline, Res Triangle Park, NC;

2) GlaxoSmithKline, Stevenage, UK;

3) GlaxoSmithKline, Upper Merion, Pennsylvania, USA;

4) Uppsala Clinical Research Center, Department of Medical Sciences, Uppsala University, Uppsala, Sweden;

5) 5Green Lane Cardiovascular Service, Auckland Cty Hospital, Auckland, New Zealand.

STABILITY is an ongoing phase III cardiovascular outcomes study that compares the effects of darapladib enteric coated (EC) tablets, 160 mg versus placebo, when added to the standard of care, on the incidence of major adverse cardiovascular events (MACE) in subjects with chronic coronary heart disease (CHD). Blood samples for determination of the LpPLA2 activity level in plasma and for extraction of DNA was obtained at randomization. To identify genetic variants that may predict response to darapladib, we genotyped ~900K common and low frequency coding variations using Illumina OmniExpress GWAS plus exome chip in advance of study completion. Among the 15828 Intent-to-Treat recruited subjects, 13674 (86%) provided informed consent for genetic analysis. Our pharmacogenetic (PGx) analysis group is comprised of subjects from 39 countries on five continents, including 10139 Whites of European heritage, 1682 Asians of East Asian or Japanese heritage, 414 Asians of Central/South Asian heritage, 268 Blacks, 1027 Hispanics and 144 others. Here we report association analysis of baseline levels of LpPLA2 to support future PGx analysis of drug response post trial completion. Among the 911375 variants genotyped, 213540 (23%) were rare (MAF < 0.5%).

Our analyses were focused on the drug target, LpPLA2 enzyme activity measured at baseline. GWAS analysis of LpPLA2 activity adjusting for age, gender and top 20 principle component scores identified 58 variants surpassing GWAS-significant threshold (5e-08).

Genome-wide stepwise regression analyses identified multiple independent associations from PLA2G7, CELSR2, APOB, KIF6, and APOE, reflecting the dependency of LpPLA2 on LDL-cholesterol levels. Most notably, several low frequency and rare coding variants in PLA2G7 were identified to be strongly associated with LpPLA2 activity. They are V279F (MAF=1.0%, P= 1.7e-108), a previously known association, and four novel associations due to I1317N (MAF=0.05%, P=4.9e-8), Q287X (MAF=0.05%, P=1.6e-7), T278M (MAF=0.02%, P=7.6e-5) and L389S (MAF=0.04%, P=4.3e-4).

All these variants had enzyme activity lowering effects and each appeared to be specific to certain ethnicity. Our comprehensive PGx analyses of baseline data has already provided great insight into common and rare coding genetic variants associated with drug target and related traits and this knowledge will be invaluable in facilitating future PGx investigation of darapladib response.

SOURCE

http://www.ashg.org/2013meeting/pdf/46025_Platform_bookmark%20for%20Web%20Final%20from%20AGS.pdf

Synthetic Biology: On Advanced Genome Interpretation for

  • Gene Variants and
  • Pathways,
  • Inversion Polymorphism,
  • Passenger Deletions,
  • De Novo Mutations,
  • Whole Genome Sequencing w/Linkage Analysis

What is the Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging?

In a recent publication by my colleague, Stephen J. Williams, Ph.D. on  5/15/2013 titled

Finding the Genetic Links in Common Disease:  Caveats of Whole Genome Sequencing Studies

http://pharmaceuticalintelligence.com/2013/05/15/finding-the-genetic-links-in-common-disease-caveats-of-whole-genome-sequencing-studies/

we learned that:

  • Groups of variants in the same gene confirmed link between APOC3 and higher risk for early-onset heart attack
  • No other significant gene variants linked with heart disease

APOC3 – apolipoprotein C-III – Potential Relevance to the Human Aging Process

Main reason for selection
Entry selected based on indirect or inconclusive evidence linking the gene product to ageing in humans or in one or more model systems
Description
APOC3 is involved in fat metabolism and may delay the catabolism of triglyceride-rich particles. Changes in APOC3 expression levels have been reported in aged mice [1754]. Results from mice suggest that FOXO1 may regulate the expression of APOC3 [1743]. Polymorphisms in the human APOC3 gene and promoter have been associated with lipoprotein profile, cardiovascular health, insulin (INS) sensitivity, and longevity [1756]. Therefore, APOC3 may impact on some age-related diseases, though its exact role in human ageing remains to be determined.

Cytogenetic information

Cytogenetic band
11q23.1-q2
Location
116,205,833 bp to 116,208,997 bp
Orientation
Plus strand

Display region using the UCSC Genome Browser

Protein information

Gene Ontology
Process: GO:0006869; lipid transport
GO:0016042; lipid catabolic process
GO:0042157; lipoprotein metabolic process
Function: GO:0005319; lipid transporter activity
Cellular component: GO:0005576; extracellular region
GO:0042627; chylomicron

Protein interactions and network

No interactions in records.

Retrieve sequences for APOC3

Promoter
Promoter
ORF
ORF
CDS
CDS

Homologues in model organisms

Bos taurus
APOC3_BOVI
Mus musculus
Apoc3
Pan troglodytes
APOC3

In other databases

AnAge
This species has an entry in AnAge

Selected references

  • [2125] Pollin et al. (2008) A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.PubMed
  • [1756] Atzmon et al. (2006) Lipoprotein genotype and conserved pathway for exceptional longevity in humansPubMed
  • [1755] Araki and Goto (2004) Dietary restriction in aged mice can partially restore impaired metabolism of apolipoprotein A-IV and C-IIIPubMed
  • [1743] Altomonte et al. (2004) Foxo1 mediates insulin action on apoC-III and triglyceride metabolismPubMed
  • [1754] Araki et al. (2004) Impaired lipid metabolism in aged mice as revealed by fasting-induced expression of apolipoprotein mRNAs in the liver and changes in serum lipidsPubMed
  • [1753] Panza et al. (2004) Vascular genetic factors and human longevityPubMed
  • [1752] Anisimov et al. (2001) Age-associated accumulation of the apolipoprotein C-III gene T-455C polymorphism C 

http://genomics.senescence.info/genes/entry.php?hgnc=APOC3

Apolipoprotein C-III is a protein component of very low density lipoprotein (VLDL). APOC3 inhibitslipoprotein lipase and hepatic lipase; it is thought to inhibit hepatic uptake[1] of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hypertriglyceridemia.

Clinical significance

Two novel susceptibility haplotypes (specifically, P2-S2-X1 and P1-S2-X1) have been discovered in ApoAI-CIII-AIV gene cluster on chromosome 11q23; these confer approximately threefold higher risk ofcoronary heart disease in normal[2] as well as non-insulin diabetes mellitus.[3]Apo-CIII delays the catabolism of triglyceride rich particles. Elevations of Apo-CIII found in genetic variation studies may predispose patients to non-alcoholic fatty liver disease.

  1. ^ Mendivil CO, Zheng C, Furtado J, Lel J, Sacks FM (2009). “Metabolism of VLDL and LDL containing apolipoprotein C-III and not other small apolipoproteins – R2”.Arteriosclerosis, Thrombosis and Vascular Biology 30 (2): 239–45. doi:10.1161/ATVBAHA.109.197830PMC 2818784PMID 19910636.
  2. ^ Singh PP, Singh M, Kaur TP, Grewal SS (2007). “A novel haplotype in ApoAI-CIII-AIV gene region is detrimental to Northwest Indians with coronary heart disease”. Int J Cardiol 130 (3): e93–5. doi:10.1016/j.ijcard.2007.07.029PMID 17825930.
  3. ^ Singh PP, Singh M, Gaur S, Grewal SS (2007). “The ApoAI-CIII-AIV gene cluster and its relation to lipid levels in type 2 diabetes mellitus and coronary heart disease: determination of a novel susceptible haplotype”. Diab Vasc Dis Res 4 (2): 124–29. doi:10.3132/dvdr.2007.030PMID 17654446.

In 2013 we reported on the discovery that there is a

Genetic Associations with Valvular Calcification and Aortic Stenosis

N Engl J Med 2013; 368:503-512

February 7, 2013DOI: 10.1056/NEJMoa1109034

METHODS

We determined genomewide associations with the presence of aortic-valve calcification (among 6942 participants) and mitral annular calcification (among 3795 participants), as detected by computed tomographic (CT) scanning; the study population for this analysis included persons of white European ancestry from three cohorts participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium (discovery population). Findings were replicated in independent cohorts of persons with either CT-detected valvular calcification or clinical aortic stenosis.

CONCLUSIONS

Genetic variation in the LPA locus, mediated by Lp(a) levels, is associated with aortic-valve calcification across multiple ethnic groups and with incident clinical aortic stenosis. (Funded by the National Heart, Lung, and Blood Institute and others.)

SOURCE:

N Engl J Med 2013; 368:503-512

Related Research by Author & Curator of this article:

Artherogenesis: Predictor of CVD – the Smaller and Denser LDL Particles

Cardiovascular Biomarkers

Genetics of Conduction Disease: Atrioventricular (AV) Conduction Disease (block): Gene Mutations – Transcription, Excitability, and Energy Homeostasis

Genomics & Genetics of Cardiovascular Disease Diagnoses: A Literature Survey of AHA’s Circulation Cardiovascular Genetics, 3/2010 – 3/2013

Hypertriglyceridemia concurrent Hyperlipidemia: Vertical Density Gradient Ultracentrifugation a Better Test to Prevent Undertreatment of High-Risk Cardiac Patients

Hypertension and Vascular Compliance: 2013 Thought Frontier – An Arterial Elasticity Focus

Personalized Cardiovascular Genetic Medicine at Partners HealthCare and Harvard Medical School

Genomics Orientations for Individualized Medicine Volume One

Market Readiness Pulse for Advanced Genome Interpretation and Individualized Medicine

We present below the MARKET LEADER in Interpretation of the Genomics Computations Results in the emerging new ERA of Medicine:  Genomic Medicine, Knome.com and its home grown software power house.

A second Case study in the  Advanced Genome Interpretation and Individualized Medicine presented following the Market Leader, is the Genome-Phenome Analyzer by SimulConsult, A Simultaneous Consult On Your Patient’s Diagnosis, Chestnut Hill, MA

 

2012: The Year When Genomic Medicine Started Paying Off

Luke Timmerman

An excerpt of an interesting article mentioning Knome [emphasis ours]…

Remember a couple of years ago when people commemorated the 10-year anniversary of the first draft human genome sequencing? The storyline then, in 200, was that we all went off to genome camp and only came home with a lousy T-shirt. Society, we were told, invested huge scientific resources in deciphering the code of life, and there wasn’t much of a payoff in the form of customized, personalized medicine.

That was an easy conclusion to reach then, when personalized medicine advocates could only point to a couple of effective targeted cancer drugs—Genentech’s Herceptin and Novartis’ Gleevec—and a couple of diagnostics. But that’s changing. My inbox the past week has been full of analyst reports from medical meetings, which mostly alerted readers to mere “incremental” advances with a number of genomic-based medicines and diagnostics. But that’s a matter of focusing on the trees, not the forest. This past year, we witnessed some really impressive progress from the early days of “clinical genomics” or “medical genomics.” The investment in deep understanding of genomics and biology is starting to look visionary.

The movement toward clinical genomics gathered steam back in June at the American Society of Clinical Oncology annual meeting. One of the hidden gem stories from ASCO was about little companies like Cambridge, MA-based Foundation Medicine and Cambridge, MA-based Knome that started seeing a surprising surge in demand from physicians for their services to help turn genomic data into medical information. The New York Times wrote a great story a month later about a young genomics researcher at Washington University in St. Louis who got cancer, had access to incredibly rich information about his tumors, and—after some wrestling with his insurance company—ended up getting a targeted drug nobody would have thought to prescribe without that information. And last month, I checked back on Stanford University researcher Mike Snyder, who made headlines this year using a smorgasbord of “omics” tools to correctly diagnose himself early with Type 2 diabetes, and then monitor his progress back into a healthy state–read the entire article

http://www.knome.com/knome-blog/2012-the-year-when-genomic-medicine-started-paying-off/

Knome and Real Time Genomics Ink Deal to Integrate and Sell the RTG Variant Platform on knoSYS™100 System

Partnership to bring accurate and fast genome analysis to translational researchers

CAMBRIDGE, MA –  May 6, 2013 – Knome Inc., the genome interpretation company, and Real Time Genomics, Inc., the genome analytics company, today announced that the Real Time Genomics (RTG) Variant platform will be integrated into every shipment of the knoSYS™100 interpretation system. The agreement enables customers to easily purchase the RTG analytics engine as an upgrade to the system. The product will combine two world-class commercial platforms to deliver end-to-end genome analytics and interpretation with superior accuracy and speed. Financial terms of the agreement were not disclosed.

“In the past year demand for genome interpretation has surged as translational researchers and clinicians adopt sequencing for human disease discovery and diagnosis,” said Wolfgang Daum, CEO of Knome. “Concomitant with that demand is the need for accurate and easy-to-use industrial grade analysis that meets expectations of clinical accuracy. The RTG platform is both incredibly fast and truly differentiating to customers doing family studies, and we are excited to add such a powerful platform to the knoSYS ecosystem.”

The partnership simplifies the purchasing process by allowing knoSYS customers to purchase the RTG platform directly from Knome sales representatives.

“The Knome system is a perfect complementary channel to further expand our commercial effort to bring the RTG platform to market,” said Steve Lombardi, CEO of Real Time Genomics. “Knome has built a recognizable brand around human clinical genome interpretation, and by delivering the RTG platform within their system, both companies are simplifying genomics to help customers understand human disease and guide clinical actions.”

About Knome

Knome Inc. (www.knome.com) is a leading provider of human genome interpretation systems and services. We help clients in two dozen countries identify the genetic basis of disease, tumor growth, and drug response. Designed to accelerate and industrialize the process of interpreting whole genomes, Knome’s big data technologies are helping to pave the healthcare industry’s transition to molecular-based, precision medicine.

About Real Time Genomics

Real Time Genomics (www.realtimegenomics.com) has a passion for genomics.  The company offers software tools and applications for the extraction of unique value from genomes.  Its competency lies in applying the combination of its patented core technology and deep computational expertise in algorithms to solve problems in next generation genomic analysis.  Real Time Genomics is a private San Francisco based company backed by investment from Catamount Ventures, Lightspeed Venture Partners, and GeneValue Ltd.

http://www.knome.com/knome-blog/knome-and-real-time-genomics-ink-deal-to-integrate-and-sell-the-rtg-variant-platform-on-knosys100-system/

Direct-to-Consumer Genomics Reinvents Itself

Malorye Allison

An excerpt of an interesting article mentioning Knome [emphasis ours]:

Cambridge, Massachusetts–based Knome made one of the splashiest entries into the field, but has now turned entirely to contract research. The company began providing DTC whole-genome sequencing to independently wealthy individuals at a time when the price was still sky high. The company’s first client, Dan Stoicescu, was a former biotech entrepreneur who paid $350,000 to have his genome sequenced in 2008 so he could review it “like a stock portfolio” as new genetic discoveries unfolded4. About a year later, the company was auctioning off a genome, with such frills as a dinner with renowned Harvard genomics researcher George Church, at a starting price of $68,000; at the time, a full-genome sequence came at the price of $99,000, indicating that the cost of genome sequencing has been plummeting steadily.

Now, the company’s model is very different. “We stopped working with the ‘wealthy healthy’ in 2010,” says Jonas Lee, Knome’s chief marketing officer. “The model changed as sequencing changed.” The new emphasis, he says, is now on using Knome’s technology and technical expertise for genome interpretation. Knome’s customers are researchers, pharmaceutical companies and medical institutions, such as Johns Hopkins University School of Medicine in Baltimore, which in January signed the company up to interpret 1,000 genomes for a study of genetic variants underlying asthma in African American and African Caribbean populations.

Knome is trying to advance the clinical use of genomics, working with groups that “want to be prepared for what’s ahead,” Lee says. “We work with at least 50 academic institutions and 20 pharmaceutical companies looking at variants and drug response.” Cancer and idiopathic genetic diseases are the first sweet spots for genomic sequencing, he says. Although cancer genomics has been hot for a while, a recent string of discoveries of Mendelian diseases5 made by whole-genome sequencing has lit up that field, too. Lee is also confident, however, that “chronic diseases like heart disease are right behind those.” The company also provides software tools. The price for its KnomeDiscovery sequencing and analysis service starts at about $12,000 per sample–read the entire article here.

http://www.knome.com/knome-blog/direct-to-consumer-genomics-reinvents-itself/

Regenesis: How Synthetic Biology Will Reinvent Nature and Ourselves

VIEW VIDEO

http://www.colbertnation.com/the-colbert-report-videos/419824/october-04-2012/george-church

 

Knome Software Makes Sense of the Genome

The startup’s software takes raw genome data and creates a usable report for doctors.

DNA decoder: Knome’s software can tease out medically relevant changes in DNA that could disrupt individual gene function or even a whole molecular pathway, as is highlighted here—certain mutations in the BRCA2 gene, which affects the function of many other genes, can be associated with an increased risk of breast cancer.

A genome analysis company called Knome is introducing software that could help doctors and other medical professionals identify genetic variations within a patient’s genome that are linked to diseases or drug response. This new product, available for now only to select medical institutions, is a patient-focused spin on Knome’s existing products aimed at researchers and pharmaceutical companies. The Knome software turns a patient’s raw genome sequence into a medically relevant report on disease risks and drug metabolism. The software can be run within a clinic’s own network—rather than in the cloud, as is the case with some genome-interpretation services—which keeps the information private.

Advances in DNA sequencing technology have sharply reduced the amount of time and money required to identify all three billion base pairs of DNA in a person’s genome. But the use of genomic information for medical decisions is still limited because the process creates such large volumes of data. Less than five years ago, Knome, based in Cambridge, Massachusetts, made headlines by offering what seemed then like a low price—$350,000—for a genome sequencing and profiling package. The same service now costs just a few thousand dollars.

Today, genome profiling has two main uses in the clinic. It’s part of the search for the cause of rare genetic diseases, and it generates tumor-specific profiles to help doctors discover the weaknesses of a patient’s particular cancer. But within a few years, the technique could move beyond rare diseases and cancer. The information gleaned from a patient’s genome could explain the origin of specific disease, could help save costs by allowing doctors to pretreat future diseases, or could improve the effectiveness and safety of medications by allowing doctors to prescribe drugs that are tuned to a person’s ability to metabolize drugs.

But teasing out the relevant genetic information from a patient’s genome is not trivial. To find the particular genetic variant that causes a specific disease or drug response can require expertise from many disciplines—from genetics to statistics to software engineering—and a lot of time. In any given patient’s genome, millions of places in that genome will differ from the standard of reference. The vast majority of these differences, or variants, will be unrelated to a patient’s medical condition, but determining that can take between 20 minutes and two hours for each variant, says Heidi Rehm, a clinical geneticist who directs the Laboratory for Molecular Medicine at Partners Healthcare Center for Personalized Genetic Medicine in Boston, and who will soon serve on the clinical advisory board of Knome. “If you scale that to … millions of variants, it becomes impossible.”

A software package like Knome’s can help whittle down the list based on factors such as disease type, the pattern of inheritance in a family, and the effects of given mutations on genes. Other companies have introduced Web- or cloud-based services to perform such an analysis, but Knome’s software suite can operate within a hospital’s network, which is critically important for privacy-concerned hospitals.

The greatest benefit of the widespread adoption of genomics in the clinic will come from the “clinical intelligence” doctors gain from networks of patient data, says Martin Tolar, CEO of Knome. Information about the association between certain genetic variants and disease or drug response could be anonymized—that is, no specific patient could be tied to the data—and shared among large hospital networks. Knome’s software will make it easy to share that kind of information, says Tolar.

“In the future, you could be in the situation where your physician will be able to pull the most appropriate information for your specific case that actually leads to recommendations about drugs and so forth,” he says.

http://www.technologyreview.com/news/428179/knome-software-makes-sense-of-the-genome/

An End-to-end Human Genome Interpretation System

The knoSYS™100 seamlessly integrates an interpretation application (knoSOFT) and informatics engine (kGAP) with a high-performance grid computer. Designed for whole genome, exome, and targeted NGS data, the knoSYS™100 helps labs quickly go “from reads to reports.”


 


Advanced Interpretation and Reporting Software

The knoSYS™100 ships with knoSOFT, an advanced application for managing sequence data through the informatics pipeline, filtering variants, running gene panels, classifying/interpreting variants, and reporting results.

knoSOFT has powerful and scalable multi-sample comparison features–capable of performing family studies, tumor/normal studies, and large case-control comparisons of hundreds of whole genomes.

Multiple simultaneous users (10) are supported, including technicians running sequence data through informatics pipeline, developers creating next-generation gene panels, geneticists researching causal variants, and production staff processing gene panels.

http://www.knome.com/knosys-100-overview/

Publications

View our collection of journal articles and genome research papers written by Knome employees, Knome board members, and other industry experts.

Publications by Knome employees and board members

The Top Two Axes of Variation of the Combined Dataset (MS, BD, PD, and IBD)

21 Aug 2012

Discerning the Ancestry of European Americans in Genetic Association Studies

Co-authored by Dr. David Goldstein, Clinical and Scientific board member for Knome

Author summary: Genetic association studies analyze both phenotypes (such as disease status) and genotypes (at sites of DNA variation) of a given set of individuals. … more

Pedigree and genetic risk prediction workflow

20 Aug 2012

Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence

Co-authored by Dr. George Church and Dr. Heidi Rehm, Clinical and Scientific Board Members for Knome

Author summary: An individual’s genetic profile plays an important role in determining risk for disease and response to medical therapy. The development of technologies that facilitate rapid whole-genome sequencing will provide unprecedented power in the estimation of disease risk. Here we develop methods to characterize genetic determinants of disease risk and … more

20 Aug 2012

A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia

Co-authored by Dr. David Goldstein, Clinical and Scientific board member for Knome

Author summary: Schizophrenia is a highly heritable disease. While the drugs commonly used to treat schizophrenia offer important relief from some symptoms, other symptoms are not well treated, and the drugs cause serious adverse effects in many individuals. This has fueled intense interest over the years in identifying genetic contributors to … more

fetchObject

20 Aug 2012

Whole-Genome Sequencing of a Single Proband Together with Linkage Analysis Identifies a Mendelian Disease Gene

Co-authored by Dr. David Goldstein, Clinical and Scientific board member for Knome

Author summary: Metachondromatosis (MC) is an autosomal dominant condition characterized by exostoses (osteochondromas), commonly of the hands and feet, and enchondromas of long bone metaphyses and iliac crests. MC exostoses may regress or even resolve over time, and short stature … more

19 Aug 2012

Exploring Concordance and Discordance for Return of Incidental Findings from Clinical Sequencing Co-authored by Dr. Heidi Rehm, Clinical and Scientific board member for Knome

Introduction: There is an increasing consensus that whole-exome sequencing (WES) and whole-genome sequencing (WGS) will continue to improve in accuracy and decline in price and that the use of these technologies will eventually become an integral part of clinical medicine.1–7 … more

Publications by industry experts and thought-leaders

22 Aug 2012

Rate of De Novo Mutations and the Importance of Father’s Age to Disease Risk

Augustine Kong, Michael L. Frigge, Gisli Masson, Soren Besenbacher, Patrick Sulem, Gisli Magnusson, Sigurjon A. Gudjonsson, Asgeir Sigurdsson, Aslaug Jonasdottir, Adalbjorg Jonasdottir, Wendy S. W. Wong, Gunnar Sigurdsson, G. Bragi Walters, Stacy Steinberg, Hannes Helgason, Gudmar Thorleifsson, Daniel F. Gudbjartsson, Agnar Helgason, Olafur Th. Magnusson, Unnur Thorsteinsdottir, & Kari Stefansson

Abstract: Mutations generate sequence diversity and provide a substrate for selection. The rate of de novo mutations is therefore of major importance to evolution. Here we conduct a study of genome-wide mutation rates by sequencing the entire genomes of 78 … more

15 Aug 2012

Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer

Florian L. Muller, Simona Colla, Elisa Aquilanti, Veronica E. Manzo, Giannicola Genovese, Jaclyn Lee, Daniel Eisenson, Rujuta Narurkar, Pingna Deng, Luigi Nezi, Michelle A. Lee, Baoli Hu, Jian Hu, Ergun Sahin, Derrick Ong, Eliot Fletcher-Sananikone, Dennis Ho, Lawrence Kwong, Cameron Brennan, Y. Alan Wang, Lynda Chin, & Ronald A. DePinho

Abstract: Inactivation of tumour-suppressor genes by homozygous deletion is a prototypic event in the cancer genome, yet such deletions often encompass neighbouring genes. We propose that homozygous deletions in such passenger genes can expose cancer-specific therapeutic vulnerabilities when the collaterally … more

1 Jul 2012

Structural Diversity and African Origin of the 17q21.31 Inversion Polymorphism

Karyn Meltz Steinberg, Francesca Antonacci, Peter H Sudmant, Jeffrey M Kidd, Catarina D Campbell, Laura Vives, Maika Malig, Laura Scheinfeldt, William Beggs, Muntaser Ibrahim, Godfrey Lema, Thomas B Nyambo, Sabah A Omar, Jean-Marie Bodo, Alain Froment, Michael P Donnelly, Kenneth K Kidd, Sarah A Tishkoff, & Evan E Eichler

Abstract: The 17q21.31 inversion polymorphism exists either as direct (H1) or inverted (H2) haplotypes with differential predispositions to disease and selection. We investigated its genetic diversity in 2,700 individuals, with an emphasis on African populations. We characterize eight structural haplotypes … more

http://www.knome.com/publications/

knome’s Systems & Software

Technical specifications

Connections and communications

Two networks: 40-Gigabit Infiniband QDR via a Mellanox Switch for storage traffic and HP ProCurve switch for network traffic

High performance computing cluster

Four nodes, each node with two 8-core/16 thread, 2.4Ghz, 64 bit Intel® Xeon® E5-2660 processor with 20MB cache, 128GB of DDR3 ECC 1600 memory; 2x2TB SATA drives (7,200RPM)

Metadata server

2x2TB 3.5″ drives with 6GB/sec SATA, RAID 1 and 2x300GB SSD (RAID 1)

Object storage server

Lustre array: Two 12x4TB arrays of 12 3.5″ drives with 6GB/sec serial SATA channels, each OSS powered by a 6-core Intel Xeon 64-bit processor running at 20GHz with 32GB RAM.

knoSYS_server

96TB total, 64TB useable storage (redundancy for failure tolerance). Expandable 384TB total.

Data sources

Reference genome GRCh37 (HG19)

dbSNP, v137

Condel (SIFT and PolyPhen-2)

HPO

OMIM

Exome Variant server, with allelisms and allele frequencies

1000 Genomes, with allelisms and allele frequencies

Human Gene Mutation db (HGMD)

Phastcons 46, mammalian conservation

PhyloP

Input/output formats

Input formats: kGAP accepts Illumina FASTQ and VCF 4.1 files as inputs

Output formats: annotated VCF files

Electrical and operating requirements

Line voltage: 110V to 120V AC, 200-240V (single phase)

Frequency: 50Hz to 60Hz

Current: 30A, RoSH compliant

Connection: NEMA L5-30

Operating temperature: 50° to 95° F

UPS included

Maximum operating altitude: 10,000 feet

Power consumption: 2,800 VA (peak)

Size and weight

Height 49.2 Inches (1250 mm)
Width 30.7 Inches (780 mm)
Depth 47.6 Inches (1210 mm)
Weight 394 lbs (179 kg)

Noise generation and heat dissipation

Enclosure provides 28dB of acoustic noise reduction; system suitable for placing in working lab environment

7200w of active heat dissipation

Included in the package

knoSYS™100 hardware

Knome software: knoSOFT, kGAP

Operating system: Linux (CentOS 6.3)

http://www.knome.com/knosys-100-specifications/

Our research services group uses a set of advanced software tools designed for whole genome and exome interpretation. These tools are also available to our clients through our knomeBASE informatics service. In addition to various scripts, libraries, and conversion utilities, these tools include knomeVARIANTS and knomePATHWAYS.

knomeVARIANTS

Genome_software_knomeVARIANTS

knome VARIANTS is a query kit that lets users search for candidate causal variants in studied genomes. It includes a query interface (see above), scripting libraries, and data conversion utilities.

Users select cases and controls, input a putative inheritance mode, and add sensible filter criteria (variant functional class, rarity/novelty, location in prior candidate regions, etc.) to automatically generate a sorted short-list of leading candidates. The application includes a SQL query interface to let users query the database as they wish, including by complex or novel sets of criteria.

In addition to querying, the application lets users export subsets of the database for viewing in MS Excel. Subsets can be output that target common research foci, including the following:

  • Sites implicated in phenotypes, regardless of subject genotypes
  • Sites where at least one studied genome mismatches the reference
  • Sites where a particular set of one or more genomes, but no other genomes, show a novel variant
  • Sites in phenotype-implicated genes
  • Sites with nonsense, frameshift, splice-site, or read-through variants, relative to reference
  • Sites where some but not all subject genome were called

knomePATHWAYS

Genome_software_knomePATHWAYS

knomePATHWAYS is a visualization tool that overlays variants found in each sample genome onto known gene interaction networks in order to help spot functional interactions between variants in distinct genes, and pathways enriched for variants in cases versus controls, differential drug responder groups, etc.

knomePATHWAYS integrates reference data from many sources, including GO, HPRD, and MsigDB (which includes KEGG and Reactome data). The application is particularly helpful in addressing higher-order questions, such as finding candidate genes and protein pathways, that are not readily addressed from tabular annotation data alone.

http://www.knome.com/interpretation-toolkit/

Genome-Phenome Analyzer by SimulConsult

A Simultaneous Consult On Your Patient’s Diagnosis

Clinicians can get a “simultaneous consult” about their patient’s diagnosis using SimulConsult’s diagnostic decision support software.

Using the free “phenome” version, medical professionals can enter patient findings into the software and get an initial differential diagnosis and suggestions about other useful findings, including tests.  The database used by the software has > 4,000 diagnoses, most complete for genetics and neurology.  It includes all genes in GeneTests and all diseases in GeneReviews.  The information about diseases is entered by clinicians, referenced to the literature and peer-reviewed by experts.  The software takes into account pertinent negatives, temporal information, and cost of tests, information ignored in other diagnostic approaches.  It transforms medical diagnosis by lowering costs, reducing errors and eliminating the medical diagnostic odysseys experienced by far too many patients and their families.

http://www.simulconsult.com/index.html

Using the “genome-phenome analyzer” version, a lab can combine a genome variant table with the phenotypic data entered by the referring clinician, thereby using the full power of genome + phenome to arrive at a diagnosis in seconds.  An innovative measure of pertinence of genes focuses attention on the genes accounting for the clinical picture, even if more than one gene is involved.  The referring clinician can use the results in the free phenome version of the software, for example adding information from confirmatory tests or adding new findings that develop over time.  For details, click here.

http://www.simulconsult.com/genome/index.html

Michael M. Segal MD, PhD, Founder,Chairman and Chief Scientist.  Dr. Segal did his undergraduate work at Harvard and his MD and PhD at Columbia, where his thesis project outlined rules for the types of chemical synapses that will form in a nervous system.  After his residency in pediatric neurology at Columbia, he moved to Harvard Medical School, where he joined the faculty and developed the microisland system for studying small numbers of brain neurons in culture.  Using this system, he developed a simplified model of epilepsy, work that won him national and international young investigator awards, and set the stage for later work on the molecular mechanism of attention deficit disorder.  Dr. Segal has a long history of interest in computers, and patterned the SimulConsult software after the way that experienced clinicians actually think about diagnosis.  He is on the Electronic Communication Committee of the Child Neurology Society and the Scientific Program Committee of the American Medical Informatics Association.

http://www.simulconsult.com/company/management.html

Read Full Post »

Reporter: Aviva Lev-Ari, PhD, RN

 

Synthetic Biology

This collection aims to highlight PLOS ONE‘s role in the emerging interdisciplinary field of synthetic biology. The collection has its roots in PLOS ONE‘s very first issue, which included two publications from the field and since then, the number of synthetic biology articles published by the journal has grown steadily. As the field continues to develop, this collection will be updated to include new publications, thereby tracking the evolution of this dynamic research area.

Synthetic biology occurs at the intersection of a number of traditional disciplines, including biology, chemistry, and engineering. It aims to create biological systems that can be programmed to do useful things such as producing drugs and biofuel. The interdisciplinary nature of synthetic biology can make it difficult to publish in traditional journals. PLOS ONE‘s broad scope, however, allows for the publication of work crossing many traditional research boundaries, making it an ideal venue for many different types of synthetic biology publications. In addition, the journal’s focus on rigorous peer review without considering impact has made it possible to publish a body of articles that truly reflects the multifaceted nature of this research area.

One overarching theme of synthetic biology is standardization, which can only be achieved through concerted community effort. To this end, each article published in PLOS ONE can be the start of a lively conversation. The ability to comment on articles provides the community with a means to engage in a dialogue focused on specific articles, and the “Share this Article” feature allows readers to quickly send an article they find interesting to their entire networks, because all the content is openly accessible.

Articles in the Synthetic Biology Collection are presented in order of publication date and new articles will be added as they are published. PLOS ONE welcomes submissions in this field.

Collection Citation: Synthetic Biology (2012) PLOS Collections:http://www.ploscollections.org/syntheticbiology

Image Credit: Ivan Morozov (Virginia Bioinformatics Institute)

SOURCE

http://www.ploscollections.org/article/browseIssue.action?issue=info:doi/10.1371/issue.pcol.v02.i18

PLOS ONE Launches Synthetic Biology Collection

By Rachel Bernstein
Posted: August 15, 2012

Today PLOS ONE is happy to announce the launch of the Synthetic Biology Collection, including over 50 papers published in the last six years that illustrate the many facets of this dynamically evolving research area.

Synthetic biology is an innovative emerging field that exists at the intersection of many traditional disciplines, including biology, chemistry, and engineering, with aims to create biological systems that can be programmed to do useful things like produce drugs or biofuels, among other applications. Despite its potential, the heavily interdisciplinary nature of the research can make it difficult to publish in traditional discipline-specific journals.

However, PLOS ONE’s broad scope allows for the publication of work crossing many traditional research boundaries, making it an ideal venue for many different types of synthetic biology research. For example, the papers in the collection cover topics including DNA synthesis and assembly, standardized biological “parts” akin to interchangeable mechanical parts, protein engineering, and complex network and pathway analysis and modeling, as described in theCollection Overview written by collection editors Jean Peccoud of Virginia Tech and Mark Isalan of the Centre for Genomic Regulation.

The Collection has roots in PLOS ONE’s very first issue, which included two publications from the field. Since then, the number of synthetic biology articles published in the journal has grown steadily. The collection launched today highlights selected synthetic biology articles published in PLOS ONE since 2006, and it is intended to be a growing resource that will be updated regularly with new papers as the field continues to grow and develop.

Collection Citation: Synthetic Biology (2012) PLOS Collections:http://www.ploscollections.org/syntheticbiology

Image Credit: Ivan Morozov (Virginia Bioinformatics Institute)

SOURCE

http://blogs.plos.org/everyone/2012/08/15/plos-one-launches-synthetic-biology-collection/

The PLOS ONE Synthetic Biology Collection: Six Years and Counting

Jean Peccoud, Mark Isalan

PLoS ONE:
Published 15 Aug 2012 | info:doi/10.1371/journal.pone.0043231

The PLOS ONE Synthetic Biology Collection: Six Years and Counting 

Jean Peccoud1,2*, Mark Isalan3

1 Virginia Bioinformatics Institute, Virginia Tech, Blacksburg, Virginia, United States of America, 2 Center for Systems Biology of Engineered Tissues, Institute for Critical Technologies and Applied Science, Virginia Tech, Blacksburg, Virginia, United States of America, 3 EMBL/CRG Systems Biology Research Unit, Centre for Genomic Regulation (CRG) and UPF, Barcelona, Spain

Abstract 

Since it was launched in 2006, PLOS ONE has published over fifty articles illustrating the many facets of the emerging field of synthetic biology. This article reviews these publications by organizing them into broad categories focused on DNA synthesis and assembly techniques, the development of libraries of biological parts, the use of synthetic biology in protein engineering applications, and the engineering of gene regulatory networks and metabolic pathways. Finally, we review articles that describe enabling technologies such as software and modeling, along with new instrumentation. In order to increase the visibility of this body of work, the papers have been assembled into the PLOS ONE Synthetic Biology Collection (www.ploscollections.org/synbio). Many of the innovative features of the PLOS ONE web site will help make this collection a resource that will support a lively dialogue between readers and authors of PLOS ONE synthetic biology papers. The content of the collection will be updated periodically by including relevant articles as they are published by the journal. Thus, we hope that this collection will continue to meet the publishing needs of the synthetic biology community.

Citation: Peccoud J, Isalan M (2012) The PLOS ONE Synthetic Biology Collection: Six Years and Counting. PLoS ONE 7(8): e43231. doi:10.1371/journal.pone.0043231

Editor: Wei Ning Chen, Nanyang Technological University, Singapore

 

Received: May 23, 2012; Accepted: July 16, 2012; Published: August 15, 2012

Copyright: © 2012 Peccoud, Isalan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: JP is supported by National Science Foundation Awards 0850100 and 0963988 and by grants R01-GM078989 and R01-GM095955 from the National Institutes of Health. MI is funded by FP7 ERC 201249 ZINC-HUBS, Ministerio de Ciencia e Innovacion grant MICINN BFU2010-17953 and the MEC-EMBL agreement. The funders had no role in the preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

* E-mail: peccoud@vt.edu

Introduction

Synthetic biology is an emerging transdisciplinary field at the intersection between many engineering and scientific disciplines such as biology, chemical engineering, chemistry, electrical engineering, or computer science. The scientific milestone that inspired the development of synthetic biology is often regarded as the description of two artificial gene networks in the same issue of Nature in 2000 [1][2]. However, the year 2004 marks the emergence of synthetic biology as a scientific community. This is the year of the first synthetic biology conference, the first iGEM competition –where students compete to build biological systems (http://igem.org/) ― and the creation of the synthetic biology page on Wikipedia. Two years later, the first issue of PLOS ONE included two synthetic biology articles [3][4], marking the beginning of a trend. Since then, PLOS ONE has published a large number of articles covering all aspects of the field. Synthetic biologists resolutely push the limits of their specialties in ways that few established journals have been able to appreciate. Since the result is often more “how to build something that works” rather than primary biological insight, the papers can be hard to place in classical journals. Many synthetic biology authors have benefited from the innovative PLOS ONE editorial policy to publish scientifically sound research, irrespective of its anticipated significance.

The purpose of this article is to introduce the PLOS ONE Synthetic Biology Collection (www.ploscollections.org/synbio/). The collection highlights selected synthetic biology articles published in PLOS ONE since 2006, putting them together in one place for easy perusal. The website is intended to be a growing resource that will be updated regularly.

We review the collection here by organizing it into some broad categories: DNA synthesis and assembly, Biological parts, Protein engineering, Networks and pathways, Synthetic life, Software and modeling, and Instruments. The classification is our own; since many synthetic biology papers cited in this review span more than one category, it was sometimes difficult to assign them to one category rather than another. Nonetheless, this structure should aid in navigating the 50+ papers currently included in the collection.

Summary of Papers Included in the Collection 

DNA Synthesis and Assembly

Synthetic biology projects often begin with the assembly of complicated, multi-component gene constructs. Therefore, both DNA assembly and cloning technologies are critical enablers of synthetic biology. Not surprisingly, many recent PLOS ONE papers propose methods to improve the efficiency of the fabrication step of synthetic biology projects. For example, Golden Gate Cloning [5] is a one-step DNA assembly protocol that can join at least nine distinct DNA fragments into one plasmid vector. The technique employs type IIs restriction enzymes that cut DNA at some distance from their cognate DNA-binding site, thus allowing flexibility and uniqueness in the compatible sticky ends that are generated. A related technique is GoldenBraid Assembly [6], that also uses type IIs restriction enzymes, but applies them iteratively to standardized DNA parts (see the ‘Biological parts’ section below). This allows the indefinite growth of reusable gene modules. Similarly, type IIs restriction enzymes have been used to make a hierarchical modular cloning system aimed at making eukaryotic multigene constructs [7].

‘One-pot’ assembly and cloning systems are being developed by many groups, and the ideal systems use as few standardized components as possible. Circular polymerase extension cloning (CPEC) fits into this category, using a single polymerase to assemble and clone multiple inserts with any vector, in a one-step in vitro reaction [8]. Alternatively, successive hybridization assembling (SHA) also employs a single reaction in vitro [9].

As well as cloning one desired multi-component construct, many projects require degenerate cloning or mutagenesis to make combinatorial libraries of gene variants. The OmniChange technique, which simultaneously saturates five independent codons, has therefore been developed to generate full-length gene libraries with 5 degenerate NNK-codons while avoiding PCR-amplification [10]. Large libraries of genetic sequences can be derived from oligonucleotides synthetized in a microarray, and later pooled in libraries from which more complex sequences can be derived [11]. By combining linear DNA amplification and PCR, DNA libraries with hundreds to thousands of members can be synthesized.

PCR methods themselves can have certain limitations, such as difficulties in amplifying GC-rich DNA targets. One study optimized polymerase chain assembly (PCA) and ligase chain reaction (LCR) methods for the construction of two GC-rich gene fragments implicated in tumorigenesis, IGF2R and BRAF [12]. They found that LCR was superior and benefited from the addition of DMSO and betaine.

The many synthesis and assembly methods presented in the collection can be combined to streamline the fabrication steps of synthetic biology projects, by producing collections of standardized biological parts. Standard parts are themselves a distinctive feature of synthetic biology, as reviewed below.

Biological Parts

The Registry of Standard Biological Parts (www.partsregistry.org), based on the original vision of Tom Knight, is providing a rich collection of components for synthetic biology projects. Several articles in the PLOS ONE collection reflect the importance of this resource. For example, a global analysis of the Registry clone collection [13] helped identify certain discrepancies between the sequences recorded in the database and the physical sequences of some clones in the collection. These results prompted a change in the quality control of the submissions to the Registry that has greatly improved the overall quality of the collection. Moreover, the analysis of parts usage patterns led to organizational guidelines that may help design and manage these new types of scientific resources. As most parts in the registry are for prokaryotes, a eukaryotic collection of 52 parts was developed and is available for distribution[14]. This includes multiple cloning sites (MCS), common protein tags, protein reporters and selection markers, amongst others. Furthermore, most of the parts were designed in a format to allow fusions that maintain the reading frame.

As well as standardized coding regions, synthetic biology projects require well-characterized promoters to achieve desired expression strengths. In one study, a single yeast promoter was mutated to make a fine-graded output range promoter library [15]. Transcription Activator-Like Orthogonal Repressors were then developed synthetically to control expression of these promoters in an orthogonal manner. Such orthogonality or ‘non-cross-reactivity’ is necessary for engineering larger synthetic gene circuits that do not interfere with the physiology of the biological chassis in which they operate. Mammalian synthetic promoters have also been developed by analyzing motifs found in highly active human promoters. Thus, by modulating the amount of sequences rich in GC and CpGs, custom designed promoters were obtained [16].

Finally, entirely de novo parts that are found nowhere in nature have been engineered to slot into biological systems. Using E. coli lacking conditionally essential genes, entirely new functional proteins were obtained from scaffolds of randomized 4-helix bundles, rescuing stalled growth [17]. Similarly, a synthetic ATP-binding protein, evolved entirely from non-natural sequences, was expressed in E. coli, altering the levels of intracellular ATP [18]. Protein engineering approaches are thus a potential source of many new parts, as well as forming a branch of synthetic biology in their own right.

Protein Engineering

Protein engineering can take many forms, from directed evolution methods to protein design. The PLOS ONE Synthetic Biology Collection includes a wide range of studies in this broad field.

Phage display is one of the classic tools of protein engineering, allowing combinatorial libraries of randomized proteins to be selected from the surface of bacteriophages. Phage display was used to generate a new class of binding proteins targeted to the pointed-end of actin [19]. These proteins, called synthetic antigen binders (sABs), were based on an antibody-like scaffold where sequence diversity is introduced into the binding loops using a new “reduced genetic code” phage display library.

An example of targeted protein design was the design of a dual reporter, Gemini [20]. Here, β-galactosidase (β-gal) α-fragment was fused to GFP, resulting in increased β-gal activity and some decrease in GFP sensitivity. GFP was also modified in a study where the ten proline residues of enhanced green fluorescent protein (EGFP) were replaced by (4R)- and (4S)-fluoroprolines (FPro) [21]. In this way, protein folding and stability could be tuned.

A promising advance in the field of engineering custom sequence-specific DNA-binding proteins is the use of Transcription Activator-Like (TAL) proteins. Modular TAL units specify A, C, G or T and can be concatenated to make long designer DNA-binding domains. Thus, Golden TAL Technology [22] has adapted Golden Gate Cloning [5] for engineering new TAL proteins. These were shown to function in human and plant cells and to target activation of both exogenous and endogenous genes, after fusion with a VP16 activation domain.

As well as single proteins, entire pathways can nowadays be engineered. Computational redesign was used to create new periplasmic binding proteins in plants, to act as biosensors in combination with a histidine kinase signaling cascade [23]. This resulted in transcription factor activation and ‘de-greening’ of plants in response to small-molecule stimuli. As can be seen from this example and the ones below, the move from single protein engineering to network engineering is one of the main driving forces in synthetic biology.

Networks and Pathways

One of the first, and now most-cited, synthetic biology papers in PLOS ONE was the study on fitness-induced attractor selection [3]. Here, a synthetic mutual inhibition gene network was built in E. coli, with two states, green (GFP) and red (RFP), that were mutually exclusive. By attaching a fitness pressure to one of the states (i.e. a gene required for growth in the absence of glutamine), the authors demonstrated that the cells switched stochastically into the fittest state, restoring growth. In other words, by changing to a glutamine-free medium, the red cells switched to green, even in the absence of formal signaling machinery. This work has important messages for potential new mechanisms in gene regulation, where underlying fitness pressures can ultimately determine how much a gene is expressed, simply according to need.

Other small bacterial networks have been built to include a heritable sequential memory switch, using the fim and hin inversion recombination systems [24], and an E. coli strain for use as a ‘chemical recording device’ [25]. In the latter, the authors created a synthetic chemically sensitive genetic toggle switch to activate appropriate fluorescent protein indicators (GFP, RFP) and along with a cell division inhibitor (minC). Moving to yeast, one example of network engineering was the reconstruction of a human p53-Mdm2 negative feedback module in S. cerevisiae [26]. In this example, many aspects of p53 regulation in mammals were maintained, such as Mdm2-dependent targeting of p53 for degradation, sumoylation at lysine 386 and further regulation of this process by p14ARF. In mammalian systems, a synthetic tetracycline regulator positive feedback loop was stably integrated and yielded a bimodal expression response because such cells can only be “OFF” or “ON” [27].

One unusual work in synthetic biology aimed to rewire and control cell shape in yeast, by changing the inputs into the α-factor pathway [28]. This pathway can give rise to multiple mating projections, upon prolonged activation. The authors tested genetic manipulations that ultimately gave rise to single or multiple projections, in the absence of the natural input, α-factor.

A group of papers in the collection explore ‘synthetic ecology’, where consortia of different cells interact to give patterns at a population level. For example, by engineering two strains of E. coli, one study was able to achieve synthetic biofilms with spatial self-organization [29]. The consortia achieved defined layered structures and had unexpected growth advantages. A second paper describes a systems composed of two quorum-sensing signal transduction circuits that allowed the authors to build a synthetic ecosystem where the population dynamics could be tuned by varying the environmental signals [30]. Third, quorum components were also used in a study which generated robust but unexpected oscillations in E. coli by building synthetic suicide circuits [31]. In fact, the quorum components proved to be unnecessary to achieve oscillations: there was a density-dependent plasmid amplification that gave rise to population-level negative feedback, ultimately resulting in the cycles. As in other areas of synthetic biology, the process of building systems often leads to surprises which can result in useful new engineering tools, or to a better understanding of the underlying biological processes [32].

Pathway engineering for the production of useful chemical or product synthesis is a major field within synthetic biology. For example, an engineered yeast that efficiently secretes penicillin was built by transplanting synthesis pathway components into a host that is more suited for pharmaceutical production [33]. Artemisinin derivatives are key components of malaria therapies and their synthesis is a high-profile goal of synthetic biology because extraction from slow-growing plants currently limits supply. Consequently, one study achieved high-level production of an artemisinin precursor in E. coli[34]. Another striking synthesis paper demonstrates a synthetic enzymatic pathway consisting of 13 enzymes for high-yield hydrogen production from starch and water [35]. Building such large systems is extremely challenging; as a result, these articles have received a lot of attention.

Synthetic Life

Synthetic life is among the most controversial of synthetic biology aims, and has received a lot of attention, even in the mainstream press. Public concerns of possible biological threats resulting from the misuse of these technologies prompted the development of new biosecurity policies [36].

One branch of this field is the de novo chemical synthesis and assembly of whole plasmids, viruses and genomes which are then transplanted into host cells. The pX1.0 plasmid is an example of a fully chemically-synthesized plasmid designed by calculating consensus sequences from 8 plasmids [37], while removing genes involved in antibiotic resistance and virulence. The plasmid not only replicated inE. coli, but could also self-transfer by conjugation into two other enterobacter species. A chemical synthesis approach was also used to construct whole genomes of bacteriophage G4 (around 10 kilobases in length), resulting in infectious viruses that could pass from one strain of E. coli to another[38].

One group has the ambitious long-term aim of building a synthetic chloroplast, and has begun by transplanting photosynthetic bacteria into eukaryotic cells to see whether they can achieve synthetic symbiosis [39]. Remarkably, the authors showed that some cyanobacteria were relatively harmless in zebrafish embryos, compared to E. coli. Furthermore, by engineering invasins into the cyanobacteria, they were able to invade and divide inside mammalian macrophages. Synthetic biology is only limited by our imagination, and one can speculate that entire free-living synthetic lifeforms could find their place in the collection in the not-too-distant future.

Software and Modeling

As the number of biological parts for synthetic biology increases, databases and design methods must evolve. For example, to help researchers search and retrieve biological parts, the Knowledgebase of Standard Biological Parts (SBPkb) is a Semantic Web resource for synthetic biology [40].

The collection also includes two articles presenting Computer Assisted Design software tools. Eugene is a human readable language to specify synthetic biological designs based on biological parts. It also provides a very expressive constraint system to drive the automatic creation of composite parts or devices from a collection of individual parts [41]. Alternatively, the Proto platform also provides a high-level biologically-oriented programming language [42]. Specifications are compiled from regulatory motifs, optimized, then converted into computational simulations for numerical verification.

Ultimately the design tools are only as good as the underlying mathematical models they rely on to make predictions of design behaviors. The collection includes a number of articles applying mathematical modeling approaches rooted in various engineering specialties to the design of synthetic genetic constructs.

Modeling gene networks is at the interface of systems and synthetic biology, and many PLOS ONE modeling papers aim to guide bioengineering projects. A recent example of adapting modeling for re-engineering properties into a system used a standardized synthetic yeast network from the In-vivo Reverse-engineering and Modeling Assessment (IRMA) [43]. Reverse engineering itself was used in a study which ultimately provided guidelines for chemotaxis pathway redesign [44]. Statecharts are used to describe dynamical systems, but have not been applied to gene networks. By doing so explicitly, one study was able to model network motifs and combine them in a complicated interlocked feed-forward loop network [45].

Two-component systems are common regulatory motifs in bacteria, and comprise a kinase that senses environmental signals together with a regulator that mediates the cell response. A recent study asked the question, “what happens if you add a third component that interacts with either of the other two?”[46]. Estimating the parameter space associated with a particular function is very valuable for guiding synthetic engineering approaches, as is determining whether a function is theoretically possible at all. For example, using a geometric argument, it was shown that, surprisingly, even monomer regulators can achieve bistability. This demonstrates the possibility of switch-like behavior in feedback autoloops without resorting to multimer regulators [47].

thumbnailFigure 1. Historical distribution of synthetic biology articles published by PLOS ONE.

This figure reports the number of articles in the collection published between 2006 and 2011. It shows a rapid growth of synthetic biology that reflects the growth of the journal and the increased familiarity of synthetic biologists with PLOS ONE.

doi:10.1371/journal.pone.0043231.g001

By combining experiments and computation, one study was able to derive design algorithms for altering synonymous codons in proteins, resulting in drastic expression differences of the same protein sequence[48]. For example, with DNA polymerase and single chain antibodies, expression could be predictably tuned to obtain concentrations ranging from undetectable to 30% of cellular protein. Importantly, using partial least squares regression, the authors noticed that favorable codons were predominantly those read by tRNAs that are most highly charged during amino acid starvation, not codons that are most abundant in highly expressed E. coli proteins. This is an important discovery for building genetic constructs that express appropriately inside the target cells.

Computation is a key function of biological networks and several studies in the collection present schemes to achieve this. The first is implemented at the level of chemical reactions and describes functions such as an inverter, an incrementer, a decrementer, a copier, a comparator, a multiplier, an exponentiator, a raise-to-a-power operation, and a logarithm in base two [49]. A key simplification is that the scheme uses only two reaction rates (“fast” and “slow”). A second study models a synthetic gene network to perform frequency multiplication [50]. Both of these studies assume deterministic relationships between input and outputs. Recently, the deterministic assumption has been challenged by experimental and theoretical works analyzing the importance of noise in the dynamics of gene networks [51]. This trend is illustrated in the collection by an article demonstrating that reliable timing of decision-making processes (choosing between multistable states) can be accomplished for large enough population sizes, as long as cells are globally coupled by chemical means [52]. Modeling can often reveal subtle non-intuitive designs, and, as a means of guiding synthetic biology, is likely to become an even larger field in the future.

thumbnailFigure 2. Relationships between article-level metrics.

For articles published between 2006 and 2009, there is a positive correlation between the number of times an article is cited in the scientific literature and the number of times it is viewed (A). For articles published between 2010 and 2012, there is a positive relationship between the number of views and the number of citations in the Mendeley social network (B). Metrics, such as number of views and citations in social media, give readers and authors an estimate of the scientific impact of individual articles well before they receive citations in scientific literature.

doi:10.1371/journal.pone.0043231.g002

Instruments

Nowadays, new technology and machinery is an important driving force for both primary biological discovery and for synthetic biology. A neat example is provided by the use of inkjet printer technology to provide low-cost high-resolution tools; a bacterial piezoelectric inkjet printer was designed to print out different strains of bacteria or chemicals in small droplets onto a flat surface at high resolution [53]. Another group used an inkjet for continuous dosing of diffusible regulators to a gel culture of E. coli, allowing 2D spatiotemporal regulation [54]. Precise spatiotemporal control of cells can also be achieved with microfluidics, and a recent report grew dividing yeast cells in a remarkable planar array [55]. Transient pulses of gene expression could be triggered by briefly inducing the GAL1 or MET3 promoters, resulting in coherent induction of cell division across the cell cluster. Other novel culture systems presented in the collection include the development of a 3-D cell culture system using a designer peptide nanofiber scaffold that self-assembled [4]. The peptide could be linked to functional motifs for cell adhesion, differentiation, and bone marrow homing for use with mouse adult neural stem cells.

The Synthetic Biology Collection: A Dynamic Community Resource Top

It is remarkable that the collection includes several articles originating from engineers and computer scientists who traditionally publish their work in conference proceedings rather than the journals available to life-scientists. PLOS ONE’s indifference to subject matter made it possible to publish an unprecedented body of articles that reflects the multi-faceted nature of synthetic biology. No less remarkable is the observation that PLOS ONE published several articles originating from iGEM projects[13][41][56].

Since 2006, the number of synthetic biology articles published by the journal has been growing steadily (Figure 1). This evolution is consistent with the social trends in synthetic biology that have been mapped in an interesting bibliometric analysis included in the collection [57]. This is an indication that the synthetic biology community is becoming more aware of the services provided by the journal. Looking forward, the collection will make it easier to identify synthetic biology articles among the quickly growing volume of articles published by the journal each day. The content of the collection will be updated periodically as new synthetic biology articles are published by the journal.

Although Journal Impact Factors are a widely-discredited form of evaluating the quality of individual papers, all too often they are still used. Thus, it is imperative to find a better alternative. One of the most exciting features of the PLOS ONE web site is the Metrics tab, displaying article-based metrics that can be used to assess the impact of individual articles. These metrics naturally include traditional indicators, such as the number of citations. The two articles of the collection published in 2006 have been cited 70 and 84 times so far. Almost all the articles published in 2007 and 2008 have received more than 10 citations. The lag between the publication of an article and its citation by others is well known. Fortunately, the Metrics tab also includes more innovative indicators that give the authors and readers alike a real-time estimate of the ‘impact’ of an article. The number of times an article is viewed is an important indicator. Since PLOS ONE is an online journal, all readers view articles online in one way or another. As a result, we hypothesized that the number of times an article was viewed should be a good predictor of the number of citations it will receive. Using data reported in Table S1, we analyzed the relationship between views and citation numbers for articles included in the collection that were published between 2006 and 2009. Figure 2 shows that there is a positive correlation between the two metrics. That relationship does not hold when including more recent articles because of a difference in timing between viewing and citing activities. Articles typically receive a substantial number of views in the first few months after publication, but it takes a few years before they are cited. The 20 articles of the collection published in 2011 have recorded a lot of views, but have not had the time to be cited in the literature yet.

A non-conventional form of citations displayed in the Metrics tab is the number of times an article is bookmarked in social media. We have reported the Mendeley (www.mendeley.com) data in Table S1.Figure 2 shows that there is a positive relationship between the number of views and the number of times articles are bookmarked in this network, at least for the most recent articles of the collection. Older articles are under-represented in Mendeley because this network was not available at the time these articles were published. It will be interesting to see if citations of the collection articles in social media will be a better predictor of citations in the scientific literature than the number of views.

One overarching theme of synthetic biology is standardization [58][59], which can only be achieved through concerted efforts by members of the community. The field has therefore been deeply influenced by the development of resources such as the Registry of Standard Biological Parts (www.partsregistry.org ). More recently, the development of SBOL, the Open Language for Synthetic Biology (www.sbolstandard.org) illustrates the need to agree on data formats suitable to the development of software tool chains necessary to support experimental efforts. Each article published in PLOS ONE can be the start of a lively conversation. The journal web site provides authors and readers alike with a detailed vision of community connections. The “Share this article” feature allows readers to quickly send an article they find interesting to their networks. The comments tab of the articles provides the community with means to engage in a dialogue focused on specific articles [5][35][48][55]. This feature can also be used by authors to provide updated information about the work presented in the article [13].

When working at its best, science should be an active conversation that keeps refining ideas. We believe that PLOS ONE provides the ideal venue to achieve this, and we hope that the collection will inspire further progress in synthetic biology. Ultimately, we hope that having a clear repository in PLOS ONE should further increase its attractiveness as a home for publishing synthetic biology.

Table S1.

Article-level statistics for the Synthetic Biology Collection.

(XLSX)

Author Contributions

Wrote the paper: JP MI.

References Top

  1. Elowitz MB, Leibler S (2000) A synthetic oscillatory network of transcriptional regulators. Nature 403: 335–338. FIND THIS ARTICLE ONLINE
  2. Gardner TS, Cantor CR, Collins JJ (2000) Construction of a genetic toggle switch in Escherichia coli. Nature 403: 339–342. FIND THIS ARTICLE ONLINE
  3. Kashiwagi A, Urabe I, Kaneko K, Yomo T (2006) Adaptive Response of a Gene Network to Environmental Changes by Fitness-Induced Attractor Selection. PLoS ONE 1: e49. FIND THIS ARTICLE ONLINE
  4. Gelain F, Bottai D, Vescovi A, Zhang S (2006) Designer Self-Assembling Peptide Nanofiber Scaffolds for Adult Mouse Neural Stem Cell 3-Dimensional Cultures. PLoS ONE 1: e119. FIND THIS ARTICLE ONLINE
  5. Engler C, Gruetzner R, Kandzia R, Marillonnet S (2009) Golden gate shuffling: a one-pot DNA shuffling method based on type IIs restriction enzymes. PLoS One 4: e5553. FIND THIS ARTICLE ONLINE
  6. Sarrion-Perdigones A, Falconi E, Zandalinas S, Juárez P, Fernández-del-Carmen A, et al. (2011) GoldenBraid: An Iterative Cloning System for Standardized Assembly of Reusable Genetic Modules. PLoS ONE 6: e21622. FIND THIS ARTICLE ONLINE
  7. Weber E, Engler C, Gruetzner R, Werner S, Marillonnet S (2011) A Modular Cloning System for Standardized Assembly of Multigene Constructs. PLoS ONE 6: e16765. FIND THIS ARTICLE ONLINE
  8. Quan J, Tian J (2009) Circular Polymerase Extension Cloning of Complex Gene Libraries and Pathways. PLoS ONE 4: e6441. FIND THIS ARTICLE ONLINE
  9. Jiang X, Yang J, Zhang H, Zou H, Wang C, et al. (2012) In Vitro Assembly of Multiple DNA Fragments Using Successive Hybridization. PLoS ONE 7: e30267. FIND THIS ARTICLE ONLINE
  10. Dennig A, Shivange A, Marienhagen J, Schwaneberg U (2011) OmniChange: The Sequence Independent Method for Simultaneous Site-Saturation of Five Codons. PLoS ONE 6: e26222.FIND THIS ARTICLE ONLINE
  11. Svensen N, Díaz-Mochón JJ, Bradley M (2011) Microarray generation of thousand-member oligonucleotide libraries. PLoS ONE 6: e24906. FIND THIS ARTICLE ONLINE
  12. Jensen M, Fukushima M, Davis R (2010) DMSO and Betaine Greatly Improve Amplification of GC-Rich Constructs in De Novo Synthesis. PLoS ONE 5: e11024. FIND THIS ARTICLE ONLINE
  13. Peccoud J, Blauvelt MF, Cai Y, Cooper KL, Crasta O, et al. (2008) Targeted Development of Registries of Biological Parts. PLoS ONE 3: e2671. FIND THIS ARTICLE ONLINE
  14. Constante M, Grünberg R, Isalan M (2011) A Biobrick Library for Cloning Custom Eukaryotic Plasmids. PLoS ONE 6: e23685. FIND THIS ARTICLE ONLINE
  15. Blount BA, Weenink T, Vasylechko S, Ellis T (2012) Rational Diversification of a Promoter Providing Fine-Tuned Expression and Orthogonal Regulation for Synthetic Biology. PLoS ONE 7: e33279.FIND THIS ARTICLE ONLINE
  16. Grabherr M, Pontiller J, Mauceli E, Ernst W, Baumann M, et al. (2011) Exploiting Nucleotide Composition to Engineer Promoters. PLoS ONE 6: e20136. FIND THIS ARTICLE ONLINE
  17. Fisher M, McKinley K, Bradley L, Viola S, Hecht M (2011) De Novo Designed Proteins from a Library of Artificial Sequences Function in Escherichia Coli and Enable Cell Growth. PLoS ONE 6: e15364.FIND THIS ARTICLE ONLINE
  18. Stomel J, Wilson J, León M, Stafford P, Chaput J (2009) A Man-Made ATP-Binding Protein Evolved Independent of Nature Causes Abnormal Growth in Bacterial Cells. PLoS ONE 4: e7385. FIND THIS ARTICLE ONLINE
  19. Brawley C, Uysal S, Kossiakoff A, Rock R (2010) Characterization of Engineered Actin Binding Proteins That Control Filament Assembly and Structure. PLoS ONE 5: e13960. FIND THIS ARTICLE ONLINE
  20. Martin L, Che A, Endy D (2009) Gemini, a bifunctional enzymatic and fluorescent reporter of gene expression. PLoS One 4: e7569. FIND THIS ARTICLE ONLINE
  21. Steiner T, Hess P, Bae JH, Wiltschi B, Moroder L, et al. (2008) Synthetic Biology of Proteins: Tuning GFPs Folding and Stability with Fluoroproline. PLoS ONE 3: e1680. FIND THIS ARTICLE ONLINE
  22. Weber E, Gruetzner R, Werner S, Engler C, Marillonnet S (2011) Assembly of Designer TAL Effectors by Golden Gate Cloning. PLoS ONE 6: e19722. FIND THIS ARTICLE ONLINE
  23. Antunes M, Morey K, Smith J, Albrecht K, Bowen T, et al. (2011) Programmable Ligand Detection System in Plants through a Synthetic Signal Transduction Pathway. PLoS ONE 6: e16292. FIND THIS ARTICLE ONLINE
  24. Ham T, Lee S, Keasling J, Arkin A (2008) Design and Construction of a Double Inversion Recombination Switch for Heritable Sequential Genetic Memory. PLoS ONE 3: e2815. FIND THIS ARTICLE ONLINE
  25. Bhomkar P, Materi W, Wishart D (2011) The Bacterial Nanorecorder: Engineering E. coli to Function as a Chemical Recording Device. PLoS ONE 6: e27559. FIND THIS ARTICLE ONLINE
  26. Di Ventura B, Funaya C, Antony C, Knop M, Serrano L (2008) Reconstitution of Mdm2-Dependent Post-Translational Modifications of p53 in Yeast. PLoS ONE 3: e1507. FIND THIS ARTICLE ONLINE
  27. May T, Eccleston L, Herrmann S, Hauser H, Goncalves J, et al. (2008) Bimodal and Hysteretic Expression in Mammalian Cells from a Synthetic Gene Circuit. PLoS ONE 3: e2372. FIND THIS ARTICLE ONLINE
  28. Tanaka H, Yi T-M (2009) Synthetic Morphology Using Alternative Inputs. PLoS ONE 4: e6946.FIND THIS ARTICLE ONLINE
  29. Brenner K, Arnold F (2011) Self-Organization, Layered Structure, and Aggregation Enhance Persistence of a Synthetic Biofilm Consortium. PLoS ONE 6: e16791. FIND THIS ARTICLE ONLINE
  30. Hu B, Du J, Zou R-y, Yuan Y-j (2010) An Environment-Sensitive Synthetic Microbial Ecosystem. PLoS ONE 5: e10619. FIND THIS ARTICLE ONLINE
  31. Marguet P, Tanouchi Y, Spitz E, Smith C, You L (2010) Oscillations by Minimal Bacterial Suicide Circuits Reveal Hidden Facets of Host-Circuit Physiology. PLoS ONE 5: e11909. FIND THIS ARTICLE ONLINE
  32. Elowitz M, Lim WA (2010) Build life to understand it. Nature 468: 889–890. FIND THIS ARTICLE ONLINE
  33. Gidijala L, Kiel J, Douma R, Seifar R, van Gulik W, et al. (2009) An Engineered Yeast Efficiently Secreting Penicillin. PLoS ONE 4: e8317. FIND THIS ARTICLE ONLINE
  34. Tsuruta H, Paddon C, Eng D, Lenihan J, Horning T, et al. (2009) High-Level Production of Amorpha-4,11-Diene, a Precursor of the Antimalarial Agent Artemisinin, in Escherichia coli. PLoS ONE 4: e4489. FIND THIS ARTICLE ONLINE
  35. Zhang P, Evans B, Mielenz J, Hopkins R, Adams M (2007) High-Yield Hydrogen Production from Starch and Water by a Synthetic Enzymatic Pathway. PLoS ONE 2: e456. FIND THIS ARTICLE ONLINE
  36. Adam L, Kozar M, Letort G, Mirat O, Srivastava A, et al. (2011) Strengths and limitations of the federal guidance on synthetic DNA. Nat Biotechnol 29: 208–210. FIND THIS ARTICLE ONLINE
  37. Hansen L, Bentzon-Tilia M, Bentzon-Tilia S, Norman A, Rafty L, et al. (2011) Design and Synthesis of a Quintessential Self-Transmissible IncX1 Plasmid, pX1.0. PLoS ONE 6: e19912. FIND THIS ARTICLE ONLINE
  38. Yang R, Han Y, Ye Y, Liu Y, Jiang Z, et al. (2011) Chemical Synthesis of Bacteriophage G4. PLoS ONE 6: e27062. FIND THIS ARTICLE ONLINE
  39. Agapakis C, Niederholtmeyer H, Noche R, Lieberman T, Megason S, et al. (2011) Towards a Synthetic Chloroplast. PLoS ONE 6: e18877. FIND THIS ARTICLE ONLINE
  40. Galdzicki M, Rodriguez C, Chandran D, Sauro H, Gennari J (2011) Standard Biological Parts Knowledgebase. PLoS ONE 6: e17005. FIND THIS ARTICLE ONLINE
  41. Bilitchenko L, Liu A, Cheung S, Weeding E, Xia B, et al. (2011) Eugene – A Domain Specific Language for Specifying and Constraining Synthetic Biological Parts, Devices, and Systems. PLoS ONE 6: e18882. FIND THIS ARTICLE ONLINE
  42. Beal J, Lu T, Weiss R (2011) Automatic Compilation from High-Level Biologically-Oriented Programming Language to Genetic Regulatory Networks. PLoS ONE 6: e22490. FIND THIS ARTICLE ONLINE
  43. Marucci L, Barton D, Cantone I, Ricci M, Cosma M, et al. (2009) How to Turn a Genetic Circuit into a Synthetic Tunable Oscillator, or a Bistable Switch. PLoS ONE 4: e8083. FIND THIS ARTICLE ONLINE
  44. Luo J, Wang J, Ma T, Sun Z (2010) Reverse Engineering of Bacterial Chemotaxis Pathway via Frequency Domain Analysis. PLoS ONE 5: e9182. FIND THIS ARTICLE ONLINE
  45. Shin Y-J, Nourani M (2010) Statecharts for Gene Network Modeling. PLoS ONE 5: e9376. FIND THIS ARTICLE ONLINE
  46. Salvado B, Vilaprinyo E, Karathia H, Sorribas A, Alves R (2012) Two Component Systems: Physiological Effect of a Third Component. PLoS ONE 7: e31095. FIND THIS ARTICLE ONLINE
  47. Widder S, Macía J, Solé R (2009) Monomeric Bistability and the Role of Autoloops in Gene Regulation. PLoS ONE 4: e5399. FIND THIS ARTICLE ONLINE
  48. Welch M, Govindarajan S, Ness J, Villalobos A, Gurney A, et al. (2009) Design Parameters to Control Synthetic Gene Expression in Escherichia coli. PLoS ONE 4: e7002. FIND THIS ARTICLE ONLINE
  49. Senum P, Riedel M (2011) Rate-Independent Constructs for Chemical Computation. PLoS ONE 6: e21414. FIND THIS ARTICLE ONLINE
  50. Purcell O, di Bernardo M, Grierson C, Savery N (2011) A Multi-Functional Synthetic Gene Network: A Frequency Multiplier, Oscillator and Switch. PLoS ONE 6: e16140. FIND THIS ARTICLE ONLINE
  51. Balazsi G, van Oudenaarden A, Collins JJ (2011) Cellular decision making and biological noise: from microbes to mammals. Cell 144: 910–925. FIND THIS ARTICLE ONLINE
  52. Koseska A, Zaikin A, Kurths J, García-Ojalvo J (2009) Timing Cellular Decision Making Under Noise via Cell–Cell Communication. PLoS ONE 4: e4872. FIND THIS ARTICLE ONLINE
  53. Merrin J, Leibler S, Chuang JS (2007) Printing multistrain bacterial patterns with a piezoelectric inkjet printer. PLoS ONE 2: e663. FIND THIS ARTICLE ONLINE
  54. Cohen D, Morfino R, Maharbiz M (2009) A Modified Consumer Inkjet for Spatiotemporal Control of Gene Expression. PLoS ONE 4: e7086. FIND THIS ARTICLE ONLINE
  55. Charvin G, Cross FR, Siggia ED (2008) A microfluidic device for temporally controlled gene expression and long-term fluorescent imaging in unperturbed dividing yeast cells. PLoS One 3: e1468. FIND THIS ARTICLE ONLINE
  56. Hesselman MC, Odoni DI, Ryback BM, de Groot S, van Heck RG, et al. (2012) A multi-platform flow device for microbial (co-) cultivation and microscopic analysis. PLoS One 7: e36982. FIND THIS ARTICLE ONLINE
  57. Oldham P, Hall S, Burton G (2012) Synthetic biology: mapping the scientific landscape. PLoS One 7: e34368. FIND THIS ARTICLE ONLINE
  58. Endy D (2005) Foundations for engineering biology. Nature 438: 449–453. FIND THIS ARTICLE ONLINE
  59. Canton B, Labno A, Endy D (2008) Refinement and standardization of synthetic biological parts and devices. Nat Biotechnol 26: 787–793. FIND THIS ARTICLE ONLINE
SOURCE

Research Articles

A Multi-Platform Flow Device for Microbial (Co-) Cultivation and Microscopic Analysis

Matthijn C. Hesselman, Dorett I. Odoni, Brendan M. Ryback, Suzette de Groot, Ruben G. A. van Heck, Jaap Keijsers, Pim Kolkman, David Nieuwenhuijse, Youri M. van Nuland, Erik Sebus, Rob Spee, Hugo de Vries, Marten T. Wapenaar, Colin J. Ingham, Karin Schroën, Vítor A. P. Martins dos Santos, Sebastiaan K. Spaans, Floor Hugenholtz, Mark W. J. van Passel

PLoS ONE:
Published 14 May 2012 | info:doi/10.1371/journal.pone.0036982

Synthetic Biology: Mapping the Scientific Landscape

Paul Oldham, Stephen Hall, Geoff Burton

PLoS ONE:
Published 23 Apr 2012 | info:doi/10.1371/journal.pone.0034368

Rational Diversification of a Promoter Providing Fine-Tuned Expression and Orthogonal Regulation for Synthetic Biology

Benjamin A. Blount, Tim Weenink, Serge Vasylechko, Tom Ellis

PLoS ONE:
Published 19 Mar 2012 | info:doi/10.1371/journal.pone.0033279

Two Component Systems: Physiological Effect of a Third Component

Baldiri Salvado, Ester Vilaprinyo, Hiren Karathia, Albert Sorribas, Rui Alves

PLoS ONE:
Published 17 Feb 2012 | info:doi/10.1371/journal.pone.0031095

In Vitro Assembly of Multiple DNA Fragments Using Successive Hybridization

Xinglin Jiang, Jianming Yang, Haibo Zhang, Huibin Zou, Cong Wang, Mo Xian

PLoS ONE:
Published 26 Jan 2012 | info:doi/10.1371/journal.pone.0030267

The Bacterial Nanorecorder: Engineering E. coli to Function as a Chemical Recording Device

Prasanna Bhomkar, Wayne Materi, David S. Wishart

PLoS ONE:
Published 23 Nov 2011 | info:doi/10.1371/journal.pone.0027559

Chemical Synthesis of Bacteriophage G4

Ruilin Yang, Yonghua Han, Yiwang Ye, Yuchen Liu, Zhimao Jiang, Yaoting Gui, Zhiming Cai

PLoS ONE:
Published 16 Nov 2011 | info:doi/10.1371/journal.pone.0027062

OmniChange: The Sequence Independent Method for Simultaneous Site-Saturation of Five Codons

Alexander Dennig, Amol V. Shivange, Jan Marienhagen, Ulrich Schwaneberg

PLoS ONE:
Published 19 Oct 2011 | info:doi/10.1371/journal.pone.0026222

Microarray Generation of Thousand-Member Oligonucleotide Libraries

Nina Svensen, Juan José Díaz-Mochón, Mark Bradley

PLoS ONE:
Published 23 Sep 2011 | info:doi/10.1371/journal.pone.0024906

A Biobrick Library for Cloning Custom Eukaryotic Plasmids

Marco Constante, Raik Grünberg, Mark Isalan

PLoS ONE:
Published 25 Aug 2011 | info:doi/10.1371/journal.pone.0023685

Automatic Compilation from High-Level Biologically-Oriented Programming Language to Genetic Regulatory Networks

Jacob Beal, Ting Lu, Ron Weiss

PLoS ONE:
Published 05 Aug 2011 | info:doi/10.1371/journal.pone.0022490

GoldenBraid: An Iterative Cloning System for Standardized Assembly of Reusable Genetic Modules

Alejandro Sarrion-Perdigones, Erica Elvira Falconi, Sara I. Zandalinas, Paloma Juárez, Asun Fernández-del-Carmen, Antonio Granell, Diego Orzaez

PLoS ONE:
Published 07 Jul 2011 | info:doi/10.1371/journal.pone.0021622

Rate-Independent Constructs for Chemical Computation

Phillip Senum, Marc Riedel

PLoS ONE:
Published 30 Jun 2011 | info:doi/10.1371/journal.pone.0021414

Assembly of Designer TAL Effectors by Golden Gate Cloning

Ernst Weber, Ramona Gruetzner, Stefan Werner, Carola Engler, Sylvestre Marillonnet

PLoS ONE:
Published 19 May 2011 | info:doi/10.1371/journal.pone.0019722

Design and Synthesis of a Quintessential Self-Transmissible IncX1 Plasmid, pX1.0

Lars H. Hansen, Mikkel Bentzon-Tilia, Sara Bentzon-Tilia, Anders Norman, Louise Rafty, Søren J. Sørensen

PLoS ONE:
Published 18 May 2011 | info:doi/10.1371/journal.pone.0019912

Exploiting Nucleotide Composition to Engineer Promoters

Manfred G. Grabherr, Jens Pontiller, Evan Mauceli, Wolfgang Ernst, Martina Baumann, Tara Biagi, Ross Swofford, Pamela Russell, Michael C. Zody, Federica Di Palma, Kerstin Lindblad-Toh, Reingard M. Grabherr

PLoS ONE:
Published 18 May 2011 | info:doi/10.1371/journal.pone.0020136

Eugene – A Domain Specific Language for Specifying and Constraining Synthetic Biological Parts, Devices, and Systems

Lesia Bilitchenko, Adam Liu, Sherine Cheung, Emma Weeding, Bing Xia, Mariana Leguia, J. Christopher Anderson, Douglas Densmore

PLoS ONE:
Published 29 Apr 2011 | info:doi/10.1371/journal.pone.0018882

Towards a Synthetic Chloroplast

Christina M. Agapakis, Henrike Niederholtmeyer, Ramil R. Noche, Tami D. Lieberman, Sean G. Megason, Jeffrey C. Way, Pamela A. Silver

PLoS ONE:
Published 20 Apr 2011 | info:doi/10.1371/journal.pone.0018877

Standard Biological Parts Knowledgebase

Michal Galdzicki, Cesar Rodriguez, Deepak Chandran, Herbert M. Sauro, John H. Gennari

PLoS ONE:
Published 24 Feb 2011 | info:doi/10.1371/journal.pone.0017005

A Modular Cloning System for Standardized Assembly of Multigene Constructs

Ernst Weber, Carola Engler, Ramona Gruetzner, Stefan Werner, Sylvestre Marillonnet

PLoS ONE:
Published 18 Feb 2011 | info:doi/10.1371/journal.pone.0016765

A Multi-Functional Synthetic Gene Network: A Frequency Multiplier, Oscillator and Switch

Oliver Purcell, Mario di Bernardo, Claire S. Grierson, Nigel J. Savery

PLoS ONE:
Published 17 Feb 2011 | info:doi/10.1371/journal.pone.0016140

Self-Organization, Layered Structure, and Aggregation Enhance Persistence of a Synthetic Biofilm Consortium

Katie Brenner, Frances H. Arnold

PLoS ONE:
Published 09 Feb 2011 | info:doi/10.1371/journal.pone.0016791

Programmable Ligand Detection System in Plants through a Synthetic Signal Transduction Pathway

Mauricio S. Antunes, Kevin J. Morey, J. Jeff Smith, Kirk D. Albrecht, Tessa A. Bowen, Jeffrey K. Zdunek, Jared F. Troupe, Matthew J. Cuneo, Colleen T. Webb, Homme W. Hellinga, June I. Medford

PLoS ONE:
Published 25 Jan 2011 | info:doi/10.1371/journal.pone.0016292

De Novo Designed Proteins from a Library of Artificial Sequences Function inEscherichia Coli and Enable Cell Growth

Michael A. Fisher, Kara L. McKinley, Luke H. Bradley, Sara R. Viola, Michael H. Hecht

PLoS ONE:
Published 04 Jan 2011 | info:doi/10.1371/journal.pone.0015364

Characterization of Engineered Actin Binding Proteins That Control Filament Assembly and Structure

Crista M. Brawley, Serdar Uysal, Anthony A. Kossiakoff, Ronald S. Rock

PLoS ONE:
Published 12 Nov 2010 | info:doi/10.1371/journal.pone.0013960

Oscillations by Minimal Bacterial Suicide Circuits Reveal Hidden Facets of Host-Circuit Physiology

Philippe Marguet, Yu Tanouchi, Eric Spitz, Cameron Smith, Lingchong You

PLoS ONE:
Published 30 Jul 2010 | info:doi/10.1371/journal.pone.0011909

DMSO and Betaine Greatly Improve Amplification of GC-Rich Constructs in De Novo Synthesis

Michael A. Jensen, Marilyn Fukushima, Ronald W. Davis

PLoS ONE:
Published 11 Jun 2010 | info:doi/10.1371/journal.pone.0011024

An Environment-Sensitive Synthetic Microbial Ecosystem

Bo Hu, Jin Du, Rui-yang Zou, Ying-jin Yuan

PLoS ONE:
Published 12 May 2010 | info:doi/10.1371/journal.pone.0010619

Reverse Engineering of Bacterial Chemotaxis Pathway via Frequency Domain Analysis

Junjie Luo, Jun Wang, Ting Martin Ma, Zhirong Sun

PLoS ONE:
Published 09 Mar 2010 | info:doi/10.1371/journal.pone.0009182

Statecharts for Gene Network Modeling

Yong-Jun Shin, Mehrdad Nourani

PLoS ONE:
Published 23 Feb 2010 | info:doi/10.1371/journal.pone.0009376

An Engineered Yeast Efficiently Secreting Penicillin

Loknath Gidijala, Jan A. K. W. Kiel, Rutger D. Douma, Reza M. Seifar, Walter M. van Gulik, Roel A. L. Bovenberg, Marten Veenhuis, Ida J. van der Klei

PLoS ONE:
Published 15 Dec 2009 | info:doi/10.1371/journal.pone.0008317

How to Turn a Genetic Circuit into a Synthetic Tunable Oscillator, or a Bistable Switch

Lucia Marucci, David A. W. Barton, Irene Cantone, Maria Aurelia Ricci, Maria Pia Cosma, Stefania Santini, Diego di Bernardo, Mario di Bernardo

PLoS ONE:
Published 07 Dec 2009 | info:doi/10.1371/journal.pone.0008083

Gemini, a Bifunctional Enzymatic and Fluorescent Reporter of Gene Expression

Lance Martin, Austin Che, Drew Endy

PLoS ONE:
Published 04 Nov 2009 | info:doi/10.1371/journal.pone.0007569

A Man-Made ATP-Binding Protein Evolved Independent of Nature Causes Abnormal Growth in Bacterial Cells

Joshua M. Stomel, James W. Wilson, Megan A. León, Phillip Stafford, John C. Chaput

PLoS ONE:
Published 08 Oct 2009 | info:doi/10.1371/journal.pone.0007385

A Modified Consumer Inkjet for Spatiotemporal Control of Gene Expression

Daniel J. Cohen, Roberto C. Morfino, Michel M. Maharbiz

PLoS ONE:
Published 18 Sep 2009 | info:doi/10.1371/journal.pone.0007086

Design Parameters to Control Synthetic Gene Expression in Escherichia coli

Mark Welch, Sridhar Govindarajan, Jon E. Ness, Alan Villalobos, Austin Gurney, Jeremy Minshull, Claes Gustafsson

PLoS ONE:
Published 14 Sep 2009 | info:doi/10.1371/journal.pone.0007002

Synthetic Morphology Using Alternative Inputs

Hiromasa Tanaka, Tau-Mu Yi

PLoS ONE:
Published 10 Sep 2009 | info:doi/10.1371/journal.pone.0006946

Circular Polymerase Extension Cloning of Complex Gene Libraries and Pathways

Jiayuan Quan, Jingdong Tian

PLoS ONE:
Published 30 Jul 2009 | info:doi/10.1371/journal.pone.0006441

Golden Gate Shuffling: A One-Pot DNA Shuffling Method Based on Type IIs Restriction Enzymes

Carola Engler, Ramona Gruetzner, Romy Kandzia, Sylvestre Marillonnet

PLoS ONE:
Published 14 May 2009 | info:doi/10.1371/journal.pone.0005553

Monomeric Bistability and the Role of Autoloops in Gene Regulation

Stefanie Widder, Javier Macía, Ricard Solé

PLoS ONE:
Published 30 Apr 2009 | info:doi/10.1371/journal.pone.0005399

Timing Cellular Decision Making Under Noise via Cell–Cell Communication

Aneta Koseska, Alexey Zaikin, Jürgen Kurths, Jordi García-Ojalvo

PLoS ONE:
Published 13 Mar 2009 | info:doi/10.1371/journal.pone.0004872

High-Level Production of Amorpha-4,11-Diene, a Precursor of the Antimalarial Agent Artemisinin, in Escherichia coli

Hiroko Tsuruta, Christopher J. Paddon, Diana Eng, Jacob R. Lenihan, Tizita Horning, Larry C. Anthony, Rika Regentin, Jay D. Keasling, Neil S. Renninger, Jack D. Newman

PLoS ONE:
Published 16 Feb 2009 | info:doi/10.1371/journal.pone.0004489

Design and Construction of a Double Inversion Recombination Switch for Heritable Sequential Genetic Memory

Timothy S. Ham, Sung K. Lee, Jay D. Keasling, Adam P. Arkin

PLoS ONE:
Published 30 Jul 2008 | info:doi/10.1371/journal.pone.0002815

Targeted Development of Registries of Biological Parts

Jean Peccoud, Megan F. Blauvelt, Yizhi Cai, Kristal L. Cooper, Oswald Crasta, Emily C. DeLalla, Clive Evans, Otto Folkerts, Blair M. Lyons, Shrinivasrao P. Mane, Rebecca Shelton, Matthew A. Sweede, Sally A. Waldon

PLoS ONE:
Published 16 Jul 2008 | info:doi/10.1371/journal.pone.0002671

Bimodal and Hysteretic Expression in Mammalian Cells from a Synthetic Gene Circuit

Tobias May, Lee Eccleston, Sabrina Herrmann, Hansjörg Hauser, Jorge Goncalves, Dagmar Wirth

PLoS ONE:
Published 04 Jun 2008 | info:doi/10.1371/journal.pone.0002372

Synthetic Biology of Proteins: Tuning GFPs Folding and Stability with Fluoroproline

Thomas Steiner, Petra Hess, Jae Hyun Bae, Birgit Wiltschi, Luis Moroder, Nediljko Budisa

PLoS ONE:
Published 27 Feb 2008 | info:doi/10.1371/journal.pone.0001680

Reconstitution of Mdm2-Dependent Post-Translational Modifications of p53 in Yeast

Barbara Di Ventura, Charlotta Funaya, Claude Antony, Michael Knop, Luis Serrano

PLoS ONE:
Published 30 Jan 2008 | info:doi/10.1371/journal.pone.0001507

A Microfluidic Device for Temporally Controlled Gene Expression and Long-Term Fluorescent Imaging in Unperturbed Dividing Yeast Cells

Gilles Charvin, Frederick R. Cross, Eric D. Siggia

PLoS ONE:
Published 23 Jan 2008 | info:doi/10.1371/journal.pone.0001468

Printing Multistrain Bacterial Patterns with a Piezoelectric Inkjet Printer

Jack Merrin, Stanislas Leibler, John S. Chuang

PLoS ONE:
Published 25 Jul 2007 | info:doi/10.1371/journal.pone.0000663

High-Yield Hydrogen Production from Starch and Water by a Synthetic Enzymatic Pathway

Y.-H. Percival Zhang, Barbara R. Evans, Jonathan R. Mielenz, Robert C. Hopkins, Michael W.W. Adams

PLoS ONE:
Published 23 May 2007 | info:doi/10.1371/journal.pone.0000456

Designer Self-Assembling Peptide Nanofiber Scaffolds for Adult Mouse Neural Stem Cell 3-Dimensional Cultures

Fabrizio Gelain, Daniele Bottai, Angleo Vescovi, Shuguang Zhang

PLoS ONE:
Published 27 Dec 2006 | info:doi/10.1371/journal.pone.0000119

Adaptive Response of a Gene Network to Environmental Changes by Fitness-Induced Attractor Selection

Akiko Kashiwagi, Itaru Urabe, Kunihiko Kaneko, Tetsuya Yomo

PLoS ONE:
Published 20 Dec 2006 | info:doi/10.1371/journal.pone.0000049

SOURCE

Read Full Post »

« Newer Posts